

## DRAFT SCIENTIFIC OPINION

### Scientific Opinion on Dietary Reference Values for iodine<sup>1</sup>

#### EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)<sup>2,3</sup>

European Food Safety Authority (EFSA), Parma, Italy

#### ABSTRACT

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies (NDA) derived Dietary Reference Values (DRVs) for iodine, which are provided as Adequate Intake (AI). Iodine is essential for synthesis of thyroid hormones. Through these hormones, iodine has an important role in energy-yielding metabolism and many other physiological processes. Iodine deficiency is associated with an increased frequency of goitre and hypothyroidism in a population. The AI for iodine is based on a large epidemiological study in European school-aged children showing that goitre prevalence is lowest for a urinary iodine concentration above around 100 µg/L. From this figure, a threshold urinary iodine concentration of  $\geq 100$  µg/L indicating sufficient iodine intake has been derived for school-aged children. In the absence of similar suitable data for other age groups it is proposed that this threshold also be applied for adults, infants and young children. Taking into account urinary volume and an iodine absorption efficiency of 92 %, an AI of 150 µg/day is proposed for adults. For infants aged 7–11 months and for children, AIs range between 70 µg/day and 130 µg/day. For pregnant women, an AI of 200 µg/day is proposed, taking into account the additional needs due to increased maternal thyroid hormone production and the iodine uptake by the fetus, placenta and amniotic fluid. The proposed AI for lactating women of 200 µg/day takes into account the existence of large iodine stores in conditions of adequate iodine status before pregnancy and considers that a full compensation for the iodine secreted in breast milk is not justified for the derivation of DRVs for iodine for lactating women.

© European Food Safety Authority, 20YY

#### KEY WORDS

iodine, goitre, Adequate Intake, Dietary Reference Value

<sup>1</sup> On request from the European Commission, Question No EFSA-Q-2011-01213, endorsed for public consultation on 12 December 2013.

<sup>2</sup> Panel members: Carlo Agostoni, Roberto Berni Canani, Susan Fairweather-Tait, Marina Heinonen, Hannu Korhonen, Sébastien La Vieille, Rosangela Marchelli, Ambroise Martin, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna Nowicka, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Sean (J.J.) Strain, Inge Tetens, Daniel Tomé, Dominique Turck and Hans Verhagen. Correspondence: [nda@efsa.europa.eu](mailto:nda@efsa.europa.eu)

<sup>3</sup> Acknowledgement: The Panel wishes to thank the members of the Working Group on Dietary Reference Values for minerals: Peter Aggett, Carlo Agostoni, Susan Fairweather-Tait, Marianne Geleijnse, Michael Hambidge, Ambroise Martin, Androniki Naska, Hildegard Przyrembel and Alfonso Siani for the preparatory work on this scientific opinion and the hearing expert Peter Laurberg for the support provided to this scientific opinion.

Suggested citation: EFSA NDA Panel (EFSA Panel on Dietetic Products Nutrition and Allergies), 20YY. Draft Scientific opinion on Dietary Reference Values for iodine. EFSA Journal 20YY;volume(issue):NNNN, 56 pp. doi:10.2903/j.efsa.20YY.NNNN

Available online: [www.efsa.europa.eu/efsajournal](http://www.efsa.europa.eu/efsajournal)

## SUMMARY

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver a scientific opinion on Dietary Reference Values (DRVs) for the European population, including iodine.

Iodine is an essential nutrient for mammals, being required as a mandatory structural and functional element of thyroid hormones. Through these hormones, iodine has an important role in energy-yielding metabolism and on the expression of genes that impact many physiological functions, from embryogenesis to growth and development, neurological and cognitive functions.

The clinical effects of iodine deficiency, referred to as a whole as iodine deficiency disorders, are the result of insufficient intakes leading to insufficient thyroid function. Iodine deficiency disorders are seen at all stages of development and are particularly of concern in pregnancy, in the fetus and in the infant. Chronic iodine deficiency may lead to compensatory thyroid hyperplasia with an enlargement of the thyroid gland denoted as goitre.

Intestinal absorption efficiency of ingested iodine is considered to be high (> 90 %). The thyroid is the major storage site for iodine in the body. Goitrogenous substances in foods, drinking water or cigarette smoke may inhibit the thyroidal uptake of iodide or its incorporation into the tyrosine precursors of thyroid hormones. The synthesis of normal quantities of thyroid hormones requires an adequate dietary intake of iodine. The kidney is the main route of excretion of iodine. In a steady state, the urinary iodine (UI) excretion represents more than 90 % of the dietary intake and is therefore an excellent indicator of recent iodine intakes. UI concentration has also been used to define the iodine status of a population. Concentrations of thyroglobulin, thyroid hormone T4 (thyroxine or 3,5,3',5'-tetraiodothyronine) and thyroid-stimulating hormone (TSH) in serum are also considered useful biomarkers of iodine status depending on age and population group and their iodine status. Thyroid volume and goitre prevalence are useful long-term clinical indicators of iodine status.

Iodine occurs in food and water mainly as iodide. The iodine concentration of water and foods is highly variable. The richest sources are marine products (such as fish, shellfish and molluscs), eggs and milk as well as their derivatives and iodised salt. Dietary assessment methods do not accurately quantify habitual iodine intakes.

Studies of iodine balance have provided highly variable results, with null balances observed at very different levels of intakes. In addition, balance studies performed in countries with a higher habitual iodine intake compared with most European countries are difficult to extrapolate to the European context. The same is true for results on iodine accumulation by the thyroid. Insufficient evidence is available for the factorial approach taking into account iodine needs for hormone production and iodine storage in the thyroid as well as basal iodine losses from urine, faeces and sweat. Thus, these approaches cannot be used for setting DRVs for iodine.

Health outcomes such as cognitive function in children, cancer and sub-clinical thyroid diseases in older adults were also considered but it was found that they cannot be used to derive DRVs for iodine.

For the setting of DRVs for iodine it was considered that the prevalence of thyroid volume enlargement in a population can be used to define a threshold of UI excretion and UI concentration above which the prevalence of abnormal values for thyroid volume is minimised. This threshold is based on observational studies of goitre prevalence in Central America in the 1960s and in European school-aged children. In the latter study, a prevalence of goitre below 5 % was almost systematically observed in all the areas of the study for a UI concentration above 100 µg/L. Even though this threshold has been established in school-aged children, the Panel also accepted it for adults. A UI concentration of 100 µg/L corresponds to an approximate iodine intake of 150 µg/day in adults. It was concluded that an Adequate Intake (AI) for iodine for adult men and women can be set at 150 µg/day. Accepting the threshold for UI concentration of 100 µg/L also for infants aged 7–11 months and for

children and taking into account age-specific urinary volumes and body weights, AIs of 70 µg/day to 130 µg/day were derived.

For pregnant women, endogenous T4 production is estimated to be increased by a mean of 37 µg/day, corresponding to an additional iodine demand of 25 µg/day for hormone synthesis in the thyroid. The additional requirements due to the development of the fetus, placenta and amniotic fluid were considered very low when related to the whole pregnancy (equivalent to a net transfer of 1 µg/day). Adding to this requirement the iodine needed for fetal synthesis of thyroid hormones leads to a total additional iodine intake rounded to 50 µg/day. Provided that thyroid status and iodine stores before pregnancy are adequate, an AI of 200 µg/day is proposed for pregnant women. It was considered that the information available on the relationship between iodine intake or status of pregnant women and clinical outcomes, such as maternal thyroid function, infants being born small for gestational age or infants' neurobehavioral impairment, cannot be used for setting DRVs for pregnant women.

For lactating women it was considered that iodine concentrations in breast milk of European women vary widely. It was noted that large iodine stores exist in conditions of adequate iodine status before pregnancy and lactation and that a full compensation for the iodine secreted in breast milk may not be justified for the derivation of DRVs for iodine for lactating women. Therefore, for lactating women the same AI is proposed as for pregnant women, i.e. 200 µg/day.

92	<b>TABLE OF CONTENTS</b>	
93	Abstract .....	1
94	Summary .....	2
95	Table of contents .....	4
96	Background as provided by the European Commission.....	6
97	Terms of reference as provided by the European Commission.....	6
98	Assessment .....	8
99	1. Introduction .....	8
100	2. Definition/category .....	8
101	2.1. Chemistry .....	8
102	2.2. Functions of iodine .....	8
103	2.2.1. Biological functions.....	8
104	2.2.2. Health consequences of deficiency and excess .....	8
105	2.2.2.1. Iodine deficiency disorders .....	9
106	2.2.2.2. Iodine excess .....	9
107	2.3. Physiology and metabolism .....	10
108	2.3.1. Intestinal absorption .....	10
109	2.3.2. Transport in blood .....	10
110	2.3.3. Distribution to tissues .....	10
111	2.3.4. Storage .....	11
112	2.3.5. Metabolism .....	11
113	2.3.6. Elimination .....	12
114	2.3.6.1. Urine .....	12
115	2.3.6.2. Faeces.....	12
116	2.3.6.3. Sweat.....	13
117	2.3.6.4. Breast milk.....	13
118	2.3.7. Modifications of iodine metabolism during pregnancy .....	14
119	2.3.8. Interaction with other nutrients.....	14
120	2.4. Biomarkers.....	14
121	2.4.1. Biomarkers of intake .....	14
122	2.4.2. Biomarkers of status .....	15
123	2.4.2.1. Urinary iodine (UI) .....	15
124	2.4.2.2. Serum concentration of thyroid hormones .....	15
125	2.4.2.3. Thyroid volume.....	15
126	2.5. Effects of genotype .....	16
127	3. Dietary sources and intake data .....	16
128	3.1. Dietary sources.....	16
129	3.2. Dietary intake.....	16
130	4. Overview of Dietary Reference Values and recommendations.....	17
131	4.1. Adults.....	17
132	4.2. Infants and children.....	18
133	4.3. Pregnancy.....	20
134	4.4. Lactation .....	20
135	5. Criteria on which to base Dietary Reference Values .....	21
136	5.1. Iodine balance .....	21
137	5.2. Iodine accumulation in the thyroid .....	22
138	5.3. Iodine requirement for thyroid hormone synthesis in euthyroid adults .....	23
139	5.4. Factorial approach in adults .....	23
140	5.5. Iodine intake and health consequences .....	24
141	5.5.1. Goitre.....	24
142	5.5.2. Cognitive function in children.....	26
143	5.5.3. Cancer.....	26
144	5.5.4. Sub-clinical thyroid diseases .....	26
145	5.6. Additional iodine requirement for pregnancy .....	27

146	5.6.1. Thyroid status, urinary iodine excretion and clinical outcomes .....	27
147	5.6.2. Supplementation studies during pregnancy .....	27
148	5.6.3. Additional requirement owing to modifications of maternal iodine metabolism .....	27
149	5.6.4. Additional requirement owing to the development of the fetus, placenta and amniotic	
150	fluid.....	28
151	5.6.4.1. Fetal and neonatal thyroid.....	28
152	5.6.4.2. Placenta and amniotic fluid.....	29
153	5.6.5. Conclusions on additional iodine requirement for pregnancy .....	29
154	5.7. Additional iodine requirement for lactation .....	29
155	6. Data on which to base Dietary Reference Values.....	30
156	6.1. Adults.....	30
157	6.2. Infants and young children.....	30
158	6.3. Children .....	31
159	6.4. Pregnancy.....	32
160	6.5. Lactation .....	32
161	Conclusions and recommendations .....	33
162	References .....	34
163	Appendices .....	50
164	Appendix A. Iodine concentration of human milk from healthy mothers in Europe.....	50
165	Appendix B. Urinary iodine concentrations in the European Union .....	52
166	Glossary and abbreviations .....	55

167

## BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION

The scientific advice on nutrient intakes is important as the basis of Community action in the field of nutrition, for example such advice has in the past been used as the basis of nutrition labelling. The Scientific Committee for Food (SCF) report on nutrient and energy intakes for the European Community dates from 1993. There is a need to review and if necessary to update these earlier recommendations to ensure that the Community action in the area of nutrition is underpinned by the latest scientific advice.

In 1993, the SCF adopted an opinion on nutrient and energy intakes for the European Community<sup>4</sup>. The report provided Reference Intakes for energy, certain macronutrients and micronutrients, but it did not include certain substances of physiological importance, for example dietary fibre.

Since then new scientific data have become available for some of the nutrients, and scientific advisory bodies in many European Union Member States and in the United States have reported on recommended dietary intakes. For a number of nutrients these newly established (national) recommendations differ from the reference intakes in the SCF (1993) report. Although there is considerable consensus between these newly derived (national) recommendations, differing opinions remain on some of the recommendations. Therefore, there is a need to review the existing EU Reference Intakes in the light of new scientific evidence, and taking into account the more recently reported national recommendations. There is also a need to include dietary components that were not covered in the SCF opinion of 1993, such as dietary fibre, and to consider whether it might be appropriate to establish reference intakes for other (essential) substances with a physiological effect.

In this context the EFSA is requested to consider the existing Population Reference Intakes for energy, micro- and macronutrients and certain other dietary components, to review and complete the SCF recommendations, in the light of new evidence, and in addition advise on a Population Reference Intake for dietary fibre.

For communication of nutrition and healthy eating messages to the public it is generally more appropriate to express recommendations for the intake of individual nutrients or substances in food-based terms. In this context the EFSA is asked to provide assistance on the translation of nutrient based recommendations for a healthy diet into food based recommendations intended for the population as a whole.

## TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION

In accordance with Article 29 (1)(a) and Article 31 of Regulation (EC) No. 178/2002, the Commission requests EFSA to review the existing advice of the Scientific Committee for Food on population reference intakes for energy, nutrients and other substances with a nutritional or physiological effect in the context of a balanced diet which, when part of an overall healthy lifestyle, contribute to good health through optimal nutrition.

In the first instance the EFSA is asked to provide advice on energy, macronutrients and dietary fibre. Specifically advice is requested on the following dietary components:

- Carbohydrates, including sugars;
- Fats, including saturated fatty acids, polyunsaturated fatty acids and monounsaturated fatty acids, *trans* fatty acids;
- Protein;

<sup>4</sup> Scientific Committee for Food, Nutrient and energy intakes for the European Community, Reports of the Scientific Committee for Food 31<sup>st</sup> series, Office for Official Publication of the European Communities, Luxembourg, 1993.

209 • Dietary fibre.

210 Following on from the first part of the task, the EFSA is asked to advise on population reference  
211 intakes of micronutrients in the diet and, if considered appropriate, other essential substances with a  
212 nutritional or physiological effect in the context of a balanced diet which, when part of an overall  
213 healthy lifestyle, contribute to good health through optimal nutrition.

214 Finally, the EFSA is asked to provide guidance on the translation of nutrient based dietary advice into  
215 guidance, intended for the European population as a whole, on the contribution of different foods or  
216 categories of foods to an overall diet that would help to maintain good health through optimal nutrition  
217 (food-based dietary guidelines).

218



## ASSESSMENT

### 1. Introduction

Iodine is an essential nutrient for mammals, being required as a mandatory structural and functional element of thyroid hormones. Through these hormones, iodine has an important role in energy-yielding metabolism and on the expression of genes that impact many physiological functions, from embryogenesis to growth and development, neurological and cognitive functions. Iodine deficiency remains a major public health concern in many countries, including some European countries (WHO/UNICEF, 2007b; Zimmermann and Andersson, 2011).

In 1993, the Scientific Committee for Food (SCF) derived for iodine a Lowest Threshold Intake (LTI), an Average Requirement (AR) and a Population Reference Intake (PRI) for adults and PRIs for infants, children and pregnant and lactating women (see Section 4).

### 2. Definition/category

#### 2.1. Chemistry

Iodine is a halogen with an atomic mass of 126.9 Da. It exists in the oxidation states  $-1$  ( $I^-$  anion or iodide) to  $+7$  ( $IO_4^-$  anion or periodate) but does not occur in free forms in nature. Iodides and iodates ( $IO_3^-$  anion, oxidation state  $+5$ ) occur ubiquitously in igneous rocks and soils, are liberated by weathering and erosion and leach by rainwater into surface water, the sea and oceans. In many areas of the world, the surface soil becomes progressively poorer in iodine through these leaching processes (SCF, 2002). Liberated elemental iodine evaporates into the atmosphere and is precipitated by rainfall onto the land surface. The iodides in the sea accumulate in marine organisms, whereas, on land, small amounts of iodine are taken up by plants that are subsequently ingested by herbivores. Of the known isotopes of iodine, only one is stable ( $^{127}I$ ).

In this opinion, the term iodine is used in a generic way when the precise nature of the chemical species of iodine is either not known/specified or not relevant.

#### 2.2. Functions of iodine

##### 2.2.1. Biological functions

Iodine is an obligatory constituent of thyroid hormones. The biological function of the thyroid hormones T4 (thyroxine or 3,5,3',5'-tetraiodothyronine) and T3 (3,5,3'-triiodothyronine) encompasses the regulation of mitochondrial energy metabolism as well as cellular oxidation, thermoregulation, intermediate metabolism, carbohydrate, lipid and protein metabolism and nitrogen retention. They are particularly necessary during early growth, development and maturation of most organs (SCF, 2002). The target organs are, in particular, the developing brain, affecting the development of hearing and vision (Morreale de Escobar et al., 2004; Williams, 2008), muscles and the heart (Kahaly and Dillmann, 2005), the pituitary gland and the kidney, but also the reproductive system (Krassas et al., 2010) and the bones.

The biological actions of thyroid hormones are considered as genomic through binding to T3 nuclear receptors or as non-genomic through binding of T3 to plasma membrane receptors or cytoplasmic proteins (Cheng et al., 2010).

##### 2.2.2. Health consequences of deficiency and excess

According to their thyroid status, individuals are classified as euthyroid (i.e. having normal thyroid function), hypothyroid or hyperthyroid. Various mechanisms can lead to thyroid disorders, and hypo- and hyperthyroid status can be observed in cases of both insufficient and excessive iodine intakes.



### 2.2.2.1. Iodine deficiency disorders

The clinical effects of iodine deficiency, referred to as a whole as iodine deficiency disorders (IDD), are the result of insufficient intakes leading to insufficient thyroid function (hypothyroidism). The latter can also be induced by thyroiditis and exposure to antithyroid compounds.

IDD are seen at all stages of development and are particularly of concern in pregnancy and infancy because of the risk of developmental brain damage (WHO/UNICEF/ICCIDD, 1996; WHO, 2004; WHO/UNICEF, 2007a; Zimmermann, 2009). In 2011, it was estimated that 44 % of the general population in Europe, i.e. 393 million inhabitants, had insufficient iodine intakes as evidenced by a UI concentration < 100 µg/L (Andersson et al., 2012), though this mode of evaluating iodine deficiency has been questioned because of insufficient proof that the iodine concentration in spot urine samples allows precise estimation of daily UI excretion (Andersen et al., 2008b).

Chronic iodine deficiency may lead to compensatory thyroid hyperplasia with goitre (enlarged thyroid gland). Goitre is initially diffuse but later may become nodular with the appearance of autonomous nodules, which may subsequently cause hyperthyroidism. Goitre also increases the risk of thyroid cancer. A large goitre may cause obstruction of the trachea and the oesophagus. Mild iodine deficiency is associated with goitre in 5–20 % of school children in the world (WHO/UNICEF/ICCIDD, 2007), appearing more frequently in girls. According to WHO/UNICEF/ICCIDD criteria, goitre prevalence in school children of 5–20 % with a mean UI excretion of > 50 µg/g creatinine defines mild IDD. Goitre prevalence up to 30 % with a mean UI excretion of 25–50 µg/g creatinine defines moderate IDD. Goitre prevalence > 30 % with a mean UI excretion of < 25 µg/g creatinine defines severe IDD. However, goitre prevalence shows a slow adaptation to long-term changes in iodine intake (WHO, 2004). In 2003, 16 % of the European general population had goitre (WHO/UNICEF, 2007b).

Hypothyroidism (myxoedema), observed with severe IDD, also results from hormone deficiency and is associated with reduced metabolic rate, cold intolerance, weight gain, puffy face, oedema, hoarse voice and mental sluggishness.

Maternal iodine deficiency during pregnancy results in fetal iodine deficiency. It is accompanied by higher rates of stillbirths, abortions and congenital abnormalities. It constitutes a threat to early brain development with consequent physical and mental retardation and lower cognitive and motor performance in later life (Zimmermann, 2012).

In areas with severe iodine deficiency cretinism, i.e. a condition of severely stunted growth and retarded physical and mental development owing to untreated congenital deficiency of thyroid hormones, may be endemic. The most common neurological type of cretinism is characterised by cognitive impairment, deaf mutism and spastic diplegia; the less common myxoedematous type is characterised by apathy, hypothyroidism, puffy features, growth retardation, delayed bone maturation, retarded sexual maturation and dwarfism (Delange, 1994; Chen and Hetzel, 2010; Skeaff, 2011; Zimmermann, 2012).

### 2.2.2.2. Iodine excess

Chronic excessive iodine supply can also lead to goitre, as has, for example, been observed following chronic excessive iodine intakes through water in China (Zhao et al., 2000). Long-term follow-up suggests that chronic excessive iodine intakes may accelerate the development of sub-clinical thyroid disorders to overt hypothyroidism or hyperthyroidism, increase the incidence of autoimmune thyroiditis and increase the risk of thyroid cancer (Laurberg et al., 1998; Teng et al., 2006).

The SCF (2002) adopted the value of 600 µg/day as a Tolerable Upper Intake Level (UL) for adults including pregnant and lactating women (i.e. approximately half of the value of 1 100 µg/day adopted by IOM (2001)), on the basis of dose-response studies of short duration (two weeks) and in a small number of subjects (n = 10–32). For iodine intakes of about 1 700–1 800 µg/day, the studies showed

an increased response of TSH concentrations to thyrotropin-releasing hormone (TRH) provided intravenously (Gardner et al., 1988; Paul et al., 1988), but these changes were considered marginal and not associated with any clinical adverse effects. A study by Stockton and Thomas (1978) covering a five-year exposure to approximately similar iodine intakes in which no clinical thyroid pathology occurred was also considered, and an uncertainty factor of 3 was selected to derive the UL for adults. The ULs for children were derived by adjustment of the adult UL on the basis of metabolic weight (body weight<sup>0.75</sup>).

## 2.3. Physiology and metabolism

### 2.3.1. Intestinal absorption

Ingested iodine in forms other than iodide is reduced to iodide in the gut. Iodide is almost completely absorbed by the small intestine, whereas the absorption and metabolism of iodised oils is not entirely known. The absorption efficiency of oral inorganic iodide and T3 is > 90 %; that of oral T4 is around 70–80 % (Fish et al., 1987; Hays, 1991).

Iodide absorption is reduced in the presence of humic acids in drinking water (Gaitan, 1990), and of thiocyanates, isothiocyanates, nitrates, fluorides, calcium, magnesium and iron in food and water (Ubom, 1991). IOM (2001) considered an absorption efficiency of 92 %; the few papers published thereafter are consistent with this conclusion (Jahreis et al., 2001; Aquaron et al., 2002).

The Na/I symporter is present in brush border membranes and mediates active iodine accumulation. Genetic expression of the symporter is down-regulated by iodide (Nicola et al., 2009).

### 2.3.2. Transport in blood

In blood, inorganic iodide and organic iodine are found. Total plasma iodine concentrations (inorganic and organic iodine) in euthyroid subjects range from 40 to about 80 µg/L (Allain et al., 1993; Michalke et al., 2000). Concentrations between 80 and 250 µg/L are generally associated with hyperthyroidism, whereas concentrations above 250 µg/L generally result from iodine overload with iodinated drugs.

Most organic iodine is present as T4, which accounts for more than 10 times the iodine content of T3, reverse T3 (rT3), mono-iodotyrosine (MIT) and di-iodotyrosine (DIT) (Michalke et al., 2000). T4 occurs either free (fT4) or bound to proteins, mainly to thyroxine-binding globulin (TBG) and to a lower extent to transthyretin (TTR or pre-albumin) and albumin. Less than 1 % of T3 and T4 is free in plasma (see Section 2.4.2.2).

The concentration of plasma inorganic iodide is proportional to dietary intake and ranges from 2 to 6 µg/L for usual intakes below 200 µg/day (Vought and London, 1965).

### 2.3.3. Distribution to tissues

Plasma iodide is actively taken up by the basal membrane of the thyroidal follicular cells using the Na/I symporter (Dohan and Carrasco, 2003; Bizhanova and Kopp, 2009) and concentrated 20–50 times in these cells. It is then transferred to the follicle lumen at the apical membrane by pendrin and possibly by an additional human apical iodine transporter (Twyffels et al., 2011).

The activity of the Na/I symporter is sensitive to inhibition by the contaminants perchlorate, thiocyanates, isothiocyanates and nitrates, to an extent which might be relevant at the population level when iodine intake is low (FAO/WHO, 2011; Mendez and Eftim, 2012).

Thiocyanate is abundant in cigarette smoke and exerts goitrogenic effects by competitively inhibiting iodine transport and organification (Colzani et al., 1998; Knudsen et al., 2002). Other goitrogens present in foods that inhibit the thyroidal uptake of iodide are cyanoglycosides (liberating cyanide upon enzymatic hydrolysis in the gut, which is subsequently metabolised to thiocyanate) and

glucosinolates (goitrogenic thioetherglycosides yielding upon hydrolysis, among others, the aglycones isothiocyanate, nitriles or thiocyanate).

Extrarenal clearance of iodide is assumed to represent thyroid clearance, corresponding to the capture of iodine by the thyroid gland. It is in the range of 3–40 mL of serum/minute in euthyroid subjects (McConahey et al., 1951; Berson et al., 1952), which corresponds to a capture by the thyroid of an average of 33 % (range 12–68 %) of the administered dose. There is an inverse relationship between thyroid uptake and dietary iodine intake or urinary excretion (McConahey et al., 1951; Berson et al., 1952; Fisher and Oddie, 1969a). The percentage of capture by the thyroid can change within 12–14 weeks, and sometimes faster, in response to changes in iodine intake in euthyroid subjects (Fisher and Oddie, 1969a).

Other tissue sites for iodide uptake from plasma are the salivary glands, the choroid plexus, the mammary gland, the kidneys and the gastric mucosa. Within the range of usual intakes, iodine flux in saliva is up to 10 µg/hour, depending on the level of intake (Vought and London, 1965).

#### 2.3.4. Storage

In adults with adequate iodine status, average total body iodine amounts to about 10–20 mg, of which 70–80 % is found in the thyroid containing, on average, 8–15 mg of iodine. In Germany, a mean thyroid iodine content of 10 mg was found in thyroid glands of 20 euthyroid subjects at autopsy (Reinwein et al., 1981). A study using X-ray fluorescence in 37 subjects aged 60–65 years who had lived in an area of adequate iodine supply throughout their lives (average UI concentration  $210 \pm 50$  µg/L) indicated that a wide variation in thyroid iodine content from 0.9 to 20.2 mg (mean 5.2 mg) is compatible with euthyroidism (Milakovic et al., 2006). These figures for thyroid iodine content are similar to thyroid iodine contents of 2–16 mg observed in Belgium (Jonckheer, 1987).

The thyroid iodine content at birth is around 100–300 µg and increases progressively to around 0.8–1 mg at four to six years (Widdowson and Spray, 1951).

#### 2.3.5. Metabolism

In the thyroid, the follicular cells synthesise intracellularly the glycoprotein thyroglobulin (Tg), which is then transferred to and stored in the colloidal follicle lumen. At the cell-colloid interface, iodide is oxidised and attached to the phenyl ring of Tg tyrosyl residues. This so-called organification is catalysed by thyroid peroxidase (TPO), an iron-containing enzyme, and results in the formation of MIT and DIT. Further action of TPO leads to the coupling of two DIT to give T4 or of MIT and DIT to give T3. All these iodothyronines remain attached to the Tg. About one-third of the iodine present is in the form of T3 and T4; the rest is present as MIT and DIT. When needed, T3 and T4 are released into the circulation from Tg by endosomal and lysosomal cellular proteases. Released MIT and DIT are deiodinated by a iodothyrosine deiodinase providing an efficient intrathyroidal recycling of iodide (Rokita et al., 2010).

Soy isoflavones inhibit TPO and goitre and hypothyroidism have been observed in infants fed entirely on soy-based infant formula low in or devoid of iodine (Doerge and Sheehan, 2002). These formulae, as is the case for all infant and follow-on formulae in the EU, are now enriched to contain 10 to 50 µg iodine/100 kcal.<sup>5</sup> In addition to their action on iodine uptake by the thyroid, some of these compounds block the incorporation of iodine into the tyrosine precursors of thyroid hormones and suppress T4 secretion (Doerge and Sheehan, 2002; EFSA CONTAM Panel, 2008). Water from wells containing humic substances may also block the iodination process. Goitrins present in vegetables of the brassica family and some other vegetables also inhibit TPO.

<sup>5</sup> Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive 1999/21/EC, OJ L 401, 30.12.2006, p. 1.

The thyroid hormone T4 contains 65 % by weight of iodine, and its active form T3 contains 59 %. The synthesis of normal quantities of thyroid hormones requires an adequate dietary intake of iodine but excessive intakes may inhibit thyroid function either by inhibition of iodide organification (Wolff-Chaikoff effect) or by inhibition of thyroglobulin proteolysis with reduction in hormone secretion.

Thyroid function is regulated by a feedback process: in response to a decrease in circulating T3 and T4 concentrations, TRH is secreted by the hypothalamus and stimulates the secretion of thyrotropin (or TSH) by the anterior pituitary gland. Within 15 to 20 minutes, TSH stimulates the secretion of thyroid hormones and causes an increased iodide uptake by the thyroid and an increased Tg breakdown. The thyroid gland is also controlled by interaction between growth factors, their receptors and signal transduction pathways. Epidermal and insulin-like growth factors may stimulate follicular cells to synthesise Tg (Nordic Council of Ministers, 2002). Persistent action of TSH causes hypertrophy and hyperplasia of the thyroid gland, and reduces the colloid and the stored iodine. TRH secretion is also stimulated by  $\alpha$ -noradrenergic impulses and inhibited by dopaminergic impulses. An autonomous regulation of thyroidal iodine metabolism also occurs independent of TSH (Forth et al., 1987).

T4 is produced only by the thyroid gland, whereas T3 is primarily produced by extrathyroidal deiodination of T4 in liver and kidney, brain, pituitary gland and brown fat tissue, with some (20 % in humans) deiodination taking place also in the thyroid. Removal of iodine occurs via specific iodothyronine deiodinases (Maia et al., 2011). Deiodinases show reduced activity in selenium deficiency, with consequently impaired activity of thyroid hormones (Forth et al., 1987). The deiodinases forming the active hormone T3 are inhibited by some drugs (thiouracil, propylthiouracil, propranolol and glucocorticoids).

The iodine liberated when T4 is enzymatically deiodinated to its active form T3 enters the plasma pool as iodide and is either re-used by the thyroid or excreted in the urine. T3, which is less tightly bound to proteins, enters the cells more easily.

### 2.3.6. Elimination

#### 2.3.6.1. Urine

The kidney is the main route of excretion of iodine, with more than 90 % of dietary iodine excreted in the urine (Vought and London, 1967; Nath et al., 1992). In adults with adequate iodine intake, the excess iodine not taken up by the thyroid is excreted in urine, with partial reabsorption occurring in the renal tubules. The renal iodide clearance is 30–36 mL/minute in euthyroid subjects and is significantly decreased either in impaired renal function or in myxoedema (McConahey et al., 1951; Berson et al., 1952). In comparison with habitual fluid intakes, an increase in fluid volume intake can lead to additional iodine losses: for an increase in urinary volume of one litre, additional iodine losses of around 15  $\mu$ g/day were predicted for adolescents and adult women, respectively (Johner et al., 2010).

In iodine-replete subjects (UI > 100  $\mu$ g/L according to WHO), it takes one to two weeks for UI concentrations to reflect an increase in iodine intake (for a supplemental intake of 250–1 500  $\mu$ g/day) and to reach null balance (Paul et al., 1988). In contrast, in infants and young children (six months to three years) living in a mildly iodine-deficient area (median UI concentration 50–99  $\mu$ g/L) and receiving supplemental iodine (90  $\mu$ g/day five times per week), UI progressively increased, and up to 30 weeks were needed for the stabilisation of UI concentrations at around 210  $\mu$ g/L (Delange et al., 2001). In adults with goitre (average UI concentration: 35  $\mu$ g/L), it took nine months for UI to reflect an increased iodine intake via supplements (200  $\mu$ g/day) and thus to reach null balance (Kahaly et al., 1997); for a higher dose of 500  $\mu$ g/day it took six months until null balance was reached (Kahaly et al., 1998).

#### 2.3.6.2. Faeces

The amount of iodine measured in faeces varies, with most values being between 10 and 30  $\mu$ g/day (Vought and London, 1964). A part of faecal iodine consists of thyroid hormones metabolised in the



liver to glucuronide or sulphate conjugates that are excreted in the bile (enterohepatic circulation) (Wu et al., 2005).

#### 2.3.6.3. Sweat

Early studies were in disagreement about the extent of iodine losses via sweat (Cole and Curtis, 1935; Spector et al., 1945; Harden and Alexander, 1963). Spector et al. (1945) found an iodine concentration in sweat of around 9.5 µg/L, which increased to 31.8 µg/L after a single dose of 2 mg potassium iodide, whereas Harden and Alexander (1963) concluded that iodine elimination in sweat was negligible (average 1.67 µg/L).

More recent studies confirmed that profuse sweating may result in significant iodine losses. A one-hour soccer game induced a mean iodine loss of around 50 µg (Mao et al., 2001). Despite some adaptation by a decrease in urinary excretion, profuse sweating (induced by exercise or warm environment) may lead, in the long run, to a depletion of iodine stores (Smyth and Duntas, 2005). Compared with UI concentrations, iodine concentrations in sweat appeared to be relatively constant, i.e. from 24.9 to 46.5 µg/L, compared with a range from 8.7 to 110.4 µg/L in urine of the same subjects (Mao et al., 2001). In a hot environment, total body iodine losses with sweat can reach an average of 150 µg/day (Consolazio et al., 1966), the flux ranging from 4.3 µg/h during sleep at 33 °C to 13 µg/h at 38.5 °C and 35 % relative humidity. Suzuki and Tamura (1985) and Mao et al. (1990; 2001) reported a value of 37 µg/L. Overall, iodine sweat concentrations appear to be relatively constant at around 35–40 µg/L over a large range of iodine intakes (UI from 8 to 280 µg/L) and in various climatic conditions, meaning that, in contrast to urinary excretion, sweat excretion is less adaptive.

#### 2.3.6.4. Breast milk

The expression of the Na/I symporter is up-regulated in the lactating mammary gland allowing a preferential uptake of iodine and thereafter secretion in breast milk, with the concentration in milk being 20 to 50 times higher than in plasma (Azizi and Smyth, 2009). More than 80 % of iodine is in the form of inorganic iodide, whereas T4 is < 2 µg/L and T3 is < 0.05 µg/L.

In iodine sufficiency, average breast milk iodine concentrations may be up to 150–180 µg/L (Semba and Delange, 2001; Dorea, 2002). Azizi and Smyth (2009) have reported a moderate ( $r = 0.40$ ) linear relationship between breast milk iodine concentration and UI concentration ranging from 50–400 µg/L. Andersen et al. (2013) also found only a moderate ( $r = 0.28$ ,  $p < 0.015$ ) linear relationship between UI concentration and breast milk iodine concentration; the relationship was stronger ( $r = 0.48$ ,  $p < 0.001$ ) when UI concentration was adjusted by urinary creatinine (as a proxy for fluid intake) and expressed as 24-hour UI excretion and breast milk iodine as excretion over 24 hours. In Korean women, a strong linear relationship was observed between maternal iodine intake (range 61–3 813 µg/day as estimated by 24-hour recalls and measurement of iodine in foods consumed) and the iodine concentration of mature breast milk (range 60–3 838 µg/L) ( $r = 0.82$ ,  $p < 0.0001$ ) (Moon and Kim, 1999). A high intra- and interindividual variability (25–87 % and around 90 %, respectively) in iodine content of breast milk has been reported (Kirk et al., 2007).

In colostrum, iodine concentrations ranging from 200 to 400 µg/L have been reported (Semba and Delange, 2001), and allows the cover of the peak T4 production that takes place in the newborn some hours after birth. Thereafter, iodine concentration in breast milk decreases (Costeira et al., 2009).

Iodine concentrations in breast milk of mothers of term infants in Europe are shown in Appendix A. However, most of the reported values are difficult to interpret, because sample sizes were small and not representative and information as to maternal intake of iodine supplements or smoking status is often lacking. There is a large overlap of breast milk iodine concentrations between countries classified as iodine-sufficient and iodine-deficient (Zimmermann, 2007). The SCF considered that the iodine concentration of breast milk in Europe varies between 10 and 300 µg/L; assuming an average

iodine concentration of 75 µg/L and a breast milk secretion of 0.8 L/day, a mean iodine loss of 60 µg/day was calculated (SCF, 2003).

Thiocyanate is known to inhibit the function of the Na/I symporter (see Section 2.3.3). In smoking Danish women who had similar UI concentrations but significantly higher serum thiocyanate concentrations compared with non-smoking women, milk iodine concentration on day five after delivery was only half that of non-smoking women (26 vs. 54 µg/L) (Laurberg et al., 2004).

### 2.3.7. Modifications of iodine metabolism during pregnancy

Adaptations of iodine metabolism during pregnancy include stimulation of the TSH receptor by chorionic gonadotrophin β-human chorionic gonadotropin (Yoshimura and Hershman, 1995), which is associated with a decrease in TSH (Glinioer, 1997); reduced hepatic clearance of T4-binding globulin Tg because of higher sialylation induced by high oestrogen concentrations (Ain et al., 1987); increase of the peripheral metabolism of thyroid hormones (placental de-iodination of T4 to the inactive reverse T3 form) (Roti et al., 1981); increased renal clearance of iodine by 30–50 % (Glinioer, 2007) with a fast return to pre-pregnant values after delivery (Dafnis and Sabatini, 1992; Smyth et al., 1997); and transfer to the fetus of a not yet well-defined amount of iodine and thyroid hormones (Glinioer, 2001, 2007; Patel et al., 2011). During gestation, maternal thyroid size slightly increases in iodine-deficient areas, whereas it remains constant in areas adequate for iodine (Berghout and Wiersinga, 1998). The extra demand for iodine explains the decrease in UI with advancing gestational age in areas of mild iodine deficiency (Stilwell et al., 2008).

In general, serum T4 increases, whereas free T4 decreases progressively and, at least in iodine-sufficient regions, serum iodide concentrations are not modified during pregnancy (Liberman et al., 1998). The multiple possibilities for adaptation render the picture complex: recently, in New Zealand, where there is a long history of iodine deficiency, a survey in pregnant women did not show abnormal modifications of thyroid hormones, thyroid volumes and TSH or anomalies in infant growth and development, despite a median maternal UI of around 35 µg/L (Pettigrew-Porter et al., 2011; Skeaff, 2012). In iodine-sufficient areas, hormonal concentrations at the end of pregnancy are not correlated with UI concentrations (Fister et al., 2011).

The placenta transfers maternal T4 to the fetus (Patel et al., 2011). In newborns without a thyroid, the concentration of thyroid hormone can be up to 35–70 nmol/L, suggesting that up to 40 % of T4 in fetal blood at term could originate from the mother (Vulsma et al., 1989).

### 2.3.8. Interaction with other nutrients

Iodine metabolism can be impaired by deficiencies of vitamin A, selenium, zinc, copper or iron. Owing to the importance of seleno-enzymes in thyroid hormone metabolism, the influence of selenium status has been one of the most extensively studied (Köhrle and Gärtner, 2009). These interactions are significant only when there is concomitantly a chronic high consumption of goitrogens and/or a low habitual iodine intake.

The nuclear receptors for thyroid hormones belong to a superfamily together with steroid hormones, vitamin D and retinoid receptors, which may explain overlapping effects and interactions with some nutrients (Davis et al., 2011).

## 2.4. Biomarkers

The iodine status of an individual or a population can be assessed using various indicators, and their suitability may differ according to the age group of interest (SCF, 2002; Ristić-Medić et al., 2009).

### 2.4.1. Biomarkers of intake

In a steady state, the UI excretion represents more than 90 % of the dietary intake and is therefore an excellent indicator of recent iodine intakes. UI is preferably determined in 24-hour samples and can be

expressed as a 24-hour excretion ( $\mu\text{g/day}$ ), as a concentration ( $\mu\text{g/L}$ ), or in relationship to creatinine excretion ( $\mu\text{g iodine/g creatinine}$ ) (Laurberg et al., 2007). Owing to the difficulty of 24-hour urine collections in a large number of people, urine spot samples are preferred at the population level and the median value is used to characterise the iodine status of a population (WHO/UNICEF, 2007b). At the individual level, 10 repeated collections of spot or 24-hour urinary samples are needed to assess iodine status with a 20 % precision (Andersen et al., 2008b). On the basis of a 24-hour urine volume and taking into account absorption efficiency of dietary iodine, the iodine intake corresponding to a UI concentration can be calculated (IOM, 2001). In adult populations, a median UI of  $100 \mu\text{g/L}$  corresponds to an iodine intake of  $150 \mu\text{g/day}$  (WHO/FAO, 2004).

## 2.4.2. Biomarkers of status

### 2.4.2.1. Urinary iodine (UI)

UI is usually used as an indicator of iodine intake, but has also been used to define the iodine status of a population; WHO/UNICEF/ICCIDD (2007) adopted the following thresholds of median UI concentrations to define the iodine status of a population (measured in school-aged children or in adults):  $< 20 \mu\text{g/L}$  for severe iodine deficiency,  $20\text{--}49 \mu\text{g/L}$  for moderate iodine deficiency,  $50\text{--}99 \mu\text{g/L}$  for mild iodine deficiency,  $100\text{--}199 \mu\text{g/L}$  for adequate iodine nutrition,  $200\text{--}299 \mu\text{g/L}$  likely adequate for pregnant/lactating women but possibly at slight risk of excess for other groups,  $\geq 300 \mu\text{g/L}$  for excessive intakes inducing the risk of adverse health consequences (iodine-induced hyperthyroidism, autoimmune thyroid diseases).

### 2.4.2.2. Serum concentration of thyroid hormones

All hormone determinations assess in the first place thyroid function, and only secondarily iodine status.

In a systematic review, the available evidence with regard to the usefulness of iodine status biomarkers was assessed (Ristić-Medić et al., 2009; Ristić-Medić et al., 2013). UI, serum Tg, serum T4 and TSH were found to be useful biomarkers of iodine status depending on age and population group and their iodine status.

Serum TSH is a suitable biomarker of iodine status in neonates and possibly in pregnant and lactating women. Measurements can be performed on dried blood spots on paper. The normal serum TSH range is  $0.1\text{--}5 \text{ mIU/L}$ , although a concentration of  $1.0$  to  $1.9 \text{ mIU/L}$  was associated with the lowest incidence of abnormal thyroid function during a five-year follow-up in subjects above 13 years at enrolment (Teng et al., 2006).

Serum Tg concentration is a useful biomarker of iodine status in children and adolescents. In iodine adequacy, the concentration of Tg is below  $10 \mu\text{g/L}$ . Methods for Tg determination on dried blood spots have been developed (Zimmermann et al., 2006).

Serum concentrations of T4 and T3 are generally less sensitive for estimating iodine status. The normal serum concentrations are around  $100 \text{ nmol/L}$  ( $80 \mu\text{g/L}$ ) for total T4 and around  $1.8 \text{ nmol/L}$  ( $1.2 \mu\text{g/L}$ ) for total T3; concentrations of the free forms are in the ranges  $11\text{--}18 \text{ pmol/L}$  and  $3.5\text{--}5 \text{ pmol/L}$ , respectively.

### 2.4.2.3. Thyroid volume

Goitre prevalence and thyroid volume are useful long-term clinical indicators of iodine status. In adults, chronic iodine deficiency causes hypothyroidism and, in the case of severe deficiency, causes up-regulation of thyroid iodine utilisation (iodide autoregulation), with an increase in uptake and many other processes including  $\text{H}_2\text{O}_2$  generation. Secondary to these changes, goitre and multinodularity tend to develop, and many elderly people will develop multinodular goitre, because of increased concentrations of TSH, leading to hyperplasia of the thyroid.



Thyroid volume is best determined from ultrasound measurements rather than by palpation which is less sensitive in the case of mild or moderate iodine deficiency. A thyroid volume exceeding 18 mL in adult women and 25 mL in adult men is generally considered to represent a goitre (Gutekunst et al., 1988). However, this generic health outcome can be measured and expressed in different ways at the population level. Thyroid size can be determined by palpation and expressed in percentages of the different stages at population level (from 0 (no goitre) to 2); thyroid volume can be given as mL, determined by thyroid ultrasonography. The results can also be expressed as the epidemiological prevalence of abnormal thyroid volume, such as the “total goitre rate” (WHO/UNICEF/ICCIDD, 2007).

## 2.5. Effects of genotype

Although mutations in proteins involved in iodine metabolism have been described and induce various forms of thyroid diseases, there are few known polymorphisms related to iodine and thyroid hormone metabolism. Genotype differences that predict differences in requirements have not yet been identified as being important at the population level (Ristić-Medić et al., 2013).

## 3. Dietary sources and intake data

### 3.1. Dietary sources

Iodine occurs in food and water mainly as iodide. Iodine can also enter the food chain via sanitising solutions and iodophores, which may provide significant amounts of iodine but are difficult to control (Phillips, 1997).

The iodine concentration of water is highly variable (e.g. from 2 to 140 µg/L in tap water in Denmark; from 0.2–15.5 µg/L (median 2.6 µg/L) and decreasing from north to south in 26 regions of Germany (Bittermann, 1999)). Iodine absorption efficiency from water is influenced by the content and nature of humic substances in water (Andersen et al., 2008a).

Sodium iodide, sodium iodate, potassium iodide and potassium iodate may be added to foods and food supplements.<sup>6</sup> Iodine readily binds to double bonds in fatty acids, allowing the preparation of iodised oils that are used for supplementation outside the EU (EFSA ANS Panel, 2013).

The iodine content of foods is highly variable between food categories as well as within each category. The richest sources are marine products (such as fish, shellfish and molluscs), eggs and milk, as well as their derivatives and iodised salt. Iodine content of milk and eggs is influenced by feeding and hygienic practices. According to WHO/UNICEF (2007b), iodine fortification of salt has been implemented in 40 European countries, being mandatory in 13 countries, voluntary in 16 and not regulated in the remaining countries; the amount of iodine added varies from 10 to 75 mg/kg salt with a majority of values in the range 15–30 mg/kg.

### 3.2. Dietary intake

Dietary assessment methods do not accurately quantify habitual iodine intakes. The lack of accuracy in measuring iodine intake from iodised salt is a major limitation of dietary assessment. In addition, the quality of iodine data in food composition tables is often poor, and depends on whether the food iodine analysis is up-to-date and to what extent natural variability in iodine content is taken into account. Food composition databases generally contain information on the salt content of foods, but they rarely specify if the salt used in processed foods is iodised or not. Because of these limitations, UI excretion as a valuable marker of iodine intake (see Section 2.4.1) is listed for various European countries in Appendix B.

<sup>6</sup> Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51; Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26.

## 4. Overview of Dietary Reference Values and recommendations

### 4.1. Adults

Because of insufficient iodine intake in some regions and for some life stages in Germany and Austria, and considering influencing factors such as iodine content in food or drinking water, the German-speaking countries (D-A-CH, 2013) decided to retain the previous recommended value of 200 µg/day for adults for these countries, but chose for Switzerland the value recommended by WHO/UNICEF/ICCIDD (1996) of 150 µg/day, considering the Swiss programme of salt fortification with iodine that had been in place for decades and the consequently better iodine status in this country. For Germany and Austria, but not for Switzerland, recommended intakes differ according to age, being 200 µg/day for adults below 51 years of age and 180 µg/day from 51 years onwards.

The World Health Organization/Food and Agriculture Organization (WHO/FAO, 2004) considered that, in adults and adolescents (13 years and over) with adequate intakes of iodine, most dietary iodine finally appears in the urine (Stanbury, 1960; Delange, 1994). Median UI concentrations below 100 µg/L, corresponding to an intake of about 150 µg/day in adults, were associated with increases in median thyroid size and possibly in serum TSH and thyroglobulin values. WHO/FAO described data investigating the relationship between UI concentration and thyroid size (Delange et al., 1997), or serum TSH and thyroglobulin concentrations (Moulopoulos et al., 1988; Buchinger et al., 1997), or goitre prevalence, radioiodine uptake and thyroidal organic iodine content (Delange et al., 1993). WHO/FAO finally set a daily recommended intake of 150 µg/day (2.0 µg/kg per day) for adolescents and adults of both sexes. The requirement corresponded to the daily UI excretion and the iodine content of food in non-endemic areas (Bottazzo, 1981; Delange, 1994), as well as the intake needed to maintain both the plasma iodide concentration above the average value (1 µg/L), which is most likely associated with the onset of goitre (Wayne et al., 1964) and the iodine stores of the thyroid above the value (10 mg) below which an insufficient iodination of thyroglobulin may lead to disorders in thyroid hormone synthesis (Delange, 1994).

The Nordic countries (NMR, 2004) estimated the AR to be 100 µg/day for both adult men and adult women. This iodine intake corresponds to a plateau of iodine concentration in the thyroid gland and to iodine turnover in euthyroid subjects (IOM, 2001). The recommended intake was derived as 150 µg/day and included a safety margin for any goitrogenic substances in foods. The lower level of intake in adults was set at 70 µg/day for both sexes. In their recent update, the Nordic countries did not change the previous recommendations for adults, since there were no new data supporting changes (Nordic Council of Ministers, 2013).

The US Institute of Medicine (IOM, 2001) used evidence on thyroidal radioiodine accumulation to estimate the average requirement of iodine. IOM considered studies investigating iodine turnover in euthyroid adults (DeGroot, 1966; Fisher and Oddie, 1969b, 1969a), a study investigating the basal amount of excreted iodine (Vought and London, 1967), balance studies (Dworkin et al., 1966; Harrison, 1968) as well as other data (Delange et al., 1993; Dunn et al., 1998). IOM also stated that there was no evidence to suggest that the average iodine requirement was altered with ageing, or differed according to sex in adults, and no reason to adjust recommended values for smaller body weight in women. IOM therefore set an Estimated Average Requirement (EAR) of about 95 µg/day for adults. A coefficient of variation (CV) of 20 % was chosen based on half of the CV of 40 % observed in Fisher and Oddie (1969a), assuming that half of the variation observed in this study was a result of the complex experimental design and calculations. This CV of 20 % was added twice to the EAR to cover the needs of 97 to 98 % of the individuals in the group. Thus, the Recommended Daily Allowance (RDA) was derived as 150 µg/day (rounded value to the nearest 50 µg) for adults in all age groups and both sexes.

The SCF (1993) concluded that most adults maintain iodine balance and normal thyroid functions with intakes between 40 and 100 µg/day. The SCF indicated that a plateau concentration of iodide in the thyroid was achieved at an iodine intake of 100 µg/day, and that increasing intakes to 300 or

500 µg/day had no further effect on this or on reducing the incidence of goitre. An AR of 100 µg/day and a PRI of 130 µg/day were proposed, as well as an LTI of 70 µg/day, below which there may be a risk of thyroid dysfunction or “sub-optimal operation” of the thyroid (Stanbury et al., 1974; Lamberg, 1986; Phillips et al., 1988).

The UK Committee on Medical Aspects of Food Policy (COMA) (DH, 1991) did not calculate an EAR but concluded that an intake of 70 µg/day appeared to be the minimum necessary to avoid signs of goitre in a population (Stanbury et al., 1974; Lamberg, 1986) and considered this value as a Lower Reference Nutrient Intake (LRNI). To provide a margin of safety and to allow for the possible effects of different dietary patterns, the Recommended Nutrient Intake (RNI) was set at 140 µg/day.

In the Netherlands, there are no official dietary reference values for iodine intake (Health Council of the Netherlands, 2008).

An overview of DRVs for iodine for adults is presented in Table 1.

**Table 1:** Overview of Dietary Reference Values for iodine for adults

	D-A-CH (2013) (Germany, Austria)	D-A-CH (2013) (Switzerland)	WHO/FAO (2004)	NNR (2012)	Afssa (2001)	IOM (2001)	SCF (1993)	DH (1991)
Age (years)	19–51	≥ 19	≥ 13	≥ 18	≥ 19	≥ 19	≥ 18	≥ 19
PRI Males (µg/day)	200	150	150 (i.e. 2.0 µg/kg per day)	150	150	150	130	140
PRI Females (µg/day)	200	150	150 (i.e. 2.0 µg/kg per day)	150	150	150	130	140
Age (years)	≥ 51							
PRI Males (µg/day)	180							
PRI Females (µg/day)	180							

## 4.2. Infants and children

According to WHO/FAO (2004), the iodine content of human milk varies markedly according to the iodine intake of the population. Positive iodine balance was achieved only at an iodine intake of at least 15 µg/kg body weight per day in term infants (Delange et al., 1993). Based on an assumed average body weight of 6 kg for an infant of six months of age, this value corresponded to about 90 µg/day. Therefore, WHO/FAO recommended an iodine intake of 15 µg/kg body weight per day, i.e. 90 µg/day for infants, in coherence with previous recommendations of WHO/UNICEF/ICCIDD (2001). WHO/FAO also explained that high concentrations of serum TSH, indicating sub-clinical hypothyroidism with the risk of brain damage, occurred at an intake of about one-third of the recommended value, and neonatal hypothyroidism resulting in endemic cretinism occurred at an intake of about one-tenth of this value. WHO/FAO (2004) stated that the daily iodine requirement on a body weight basis decreases progressively with age. For children aged 1-5 and 6-12 years, respectively, the recommendations were 90 µg/day (6 µg/kg per day) and 120 µg/day (4 µg/kg per day), based on an average body weight of a 10-year-old child (25 kg) calculated by FAO, and a study by Tovar et al. (1969) correlating 24-hour thyroid radioiodine uptake and UI excretion in 9- to 13-year-old school children in rural Mexico. Recommendations for adolescents aged 13 years and older were the same as those for adults.

The Nordic countries (NNR, 2004) recommended intakes of 90 µg/day for children aged 2-5 years, 120 µg/day for children aged 6-9 years and 150 µg/day for children aged 10 years and over. The recommendations were based on data on goitre prevalence and UI excretion in European children

(Delange et al., 1997) and extrapolations from adults based on energy and growth requirements. These recommendations were kept unchanged in their recent update, as there were no new data supporting changes (Nordic Council of Ministers, 2013).

The IOM (2001) concluded that no functional criteria of iodine status had been demonstrated to reflect response to dietary intake in infants. Thus, for infants from birth to six months of age, an AI was derived based on an estimated iodine intake in infants exclusively fed human milk. An AI of 130 µg/day for infants aged 7-12 months was derived extrapolating from the AI for younger infants. Recommended values for older children were extrapolated from adult data or derived from balance data for a specific age group. For children aged 1-3 years, a four-day balance study (Ingenbleek and Malvaux, 1974) on children (1.5-2.5 years) previously malnourished and then nutritionally rehabilitated was considered. For children aged 4-8 years, a balance study (Malvaux et al., 1969) undertaken in children aged eight years was considered. For children aged 1-8 years, an EAR of 65 µg/day was set. The RDA of 90 µg/day was derived by adding twice a CV of 20 %. For children aged 9-18 years, the EAR was extrapolated down from adults considering metabolic body weight ( $\text{kg}^{0.75}$ ): 73 µg/day for children aged 9-13 years and 95 µg/day for children aged 14-18 years. For these age ranges, IOM then derived RDA values of 120 µg/day and 150 µg/day, respectively, considering a CV of 20 % and after rounding. For children aged 9-13 years, data on the prevalence of goitre in European boys and girls aged 6-15 years (Delange et al., 1997), and its relationship with UI excretion, were also discussed.

The SCF (1993) calculated PRIs for children from adult values on the basis of energy requirements.

The UK COMA (DH, 1991) set RNIs and LRNIs for children and which were extrapolated from the adult values using EARs for energy, as extrapolating on a weight basis would have resulted in values similar to those estimated in areas with a high incidence of goitre.

An overview of DRVs for iodine for children is presented in Table 2.

**Table 2:** Overview of Dietary Reference Values for iodine for children

	D-A-CH (2013) (Germany, Austria)	D-A-CH (2013) (Switzerland)	WHO/FAO (2004)	NNR (2012)	IOM (2001)	Afssa (2001) <sup>(c)</sup>	SCF (1993)	DH (1991)
<b>Age</b> (months)	4-12	4-12	0-59	6-11	7-12	6-12	6-11	7-12
<b>PRI</b> (µg/day)	80	50	90 (i.e. 6 µg/kg per day for 1-5 years)	50	130 <sup>(a)</sup>	90	50	60
<b>Age</b> (years)	1-4	1-4		12-23	1-3	1-3	1-3	1-3
<b>PRI</b> (µg/day)	100	90		70	90 <sup>(b)</sup>	80	70	70
<b>Age</b> (years)	4-7	4-7	6-12	2-5	4-8	4-6	4-6	4-6
<b>PRI</b> (µg/day)	120	90	120 (i.e. 4 µg/kg per day)	90	90 <sup>(b)</sup>	90	90	100
<b>Age</b> (years)	7-10	7-10	≥ 13	6-9	9-13	7-9	7-10	7-10
<b>PRI</b> (µg/day)	140	120	150	120	120 <sup>(b)</sup>	120	100	110
<b>Age</b> (years)	10-13	10-13		10-13	14-18	10-19	11-14	11-14
<b>PRI</b> (µg/day)	180	120		150	150 <sup>(b)</sup>	150	120	130
<b>Age</b> (years)	13-19	13-19		13-17			15-17	15-18

	D-A-CH (2013) (Germany, Austria)	D-A-CH (2013) (Switzerland)	WHO/FAO (2004)	NNR (2012)	IOM (2001)	Afssa (2001) <sup>(c)</sup>	SCF (1993)	DH (1991)
<b>PRI</b> (µg/day)	200	150		150			130	140

(a): Adequate Intake.

(b): Recommended Dietary Allowance.

(c): Based on values provided in the final summary table in Afssa (2001).

### 4.3. Pregnancy

D-A-CH (2013) considered the additional requirement for pregnancy owing to the increased renal clearance and the increased iodine excretion in urine, and recommended an intake of 230 µg/day for Germany and Austria and of 200 µg/day for Switzerland.

WHO/FAO (2004) indicated that the iodine requirement during pregnancy should provide for the needs of the fetus and compensate for the increased loss of iodine in the urine owing to an increased renal clearance of iodine during pregnancy (Aboul-Khair et al., 1964). WHO/FAO concluded that the iodine intake required to prevent the onset of sub-clinical hypothyroidism of mother and fetus during pregnancy, and thus to prevent the possible risk of brain damage of the fetus, was approximately 200 µg/day (Roti and Vagenakis, 2000), i.e. 3.5 µg/kg per day, in agreement with previous recommendations by WHO/UNICEF/ICCIDD (2001).

The Nordic countries (NNR, 2004) recommended an extra 25 µg/day for pregnant women to cover the needs of the fetus. Thus, the recommendation was set at 175 µg/day and was unchanged in the recent update of the Nordic Nutrition Recommendations (Nordic Council of Ministers, 2013).

The IOM (2001) set an EAR of 160 µg/day for pregnant women based on studies on thyroid iodine content of newborns (Delange et al., 1989; Braverman and Utiger, 1991) suggesting a daily thyroid iodine uptake of approximately 75 µg/day by the fetus, balance studies in full-term infants (Delange et al., 1984) and pregnant women (Dworkin et al., 1966) suggesting a mean iodine retention of a fetus with a mean weight of 3 kg of about 22 µg/day and a balance observed in pregnant women at about 160 µg/day, and studies on iodine supplementation during pregnancy (Romano et al., 1991; Pedersen et al., 1993; Berghout and Wiersinga, 1998; Glinioer, 1998). The RDA of 220 µg/day was derived by adding twice a CV of 20 % and rounding to the nearest 10 µg.

The SCF (1993) and the UK COMA (DH, 1991) did not recommend an increment for pregnant women. Therefore, the PRI for pregnancy was the same as for non-pregnant women, i.e. 130 µg/day according to the SCF and 140 µg/day according to the UK COMA. The SCF (1993) considered that, provided the pre-pregnancy iodine intake was adequate, there was no evidence that an increased dietary intake was needed during pregnancy.

### 4.4. Lactation

The German-speaking countries (D-A-CH, 2013) considered the amount of iodine excreted in human milk and recommended an intake of 260 µg/day for Germany and Austria, and 200 µg/day for Switzerland.

WHO/FAO (2004) reported the value recommended by WHO/UNICEF/ICCIDD (2001), i.e. 200 µg/day or 3.5 µg/kg per day and later proposed a daily recommendation of 250 µg/day (WHO/UNICEF/ICCIDD, 2007).

The Nordic countries (NNR, 2004) recommended an additional supply of 50 µg/day for lactating women to provide sufficient iodine in human milk, thus resulting in a recommended intake of



200 µg/day. In the recent update of the Nordic Nutrition Recommendations, this value was kept unchanged (Nordic Council of Ministers, 2013).

For lactating women, the IOM (2001) considered the average daily loss to be 114 µg of iodine in human milk (Gushurst et al., 1984) (considering an average milk excretion of 0.78 L/day and an average concentration of 146 µg/L), thus deriving an EAR of 209 µg/day and an RDA of 290 µg/day, considering a CV of 20 % and after rounding to the nearest 10 µg.

The SCF (1993) derived a PRI of 160 µg/day for lactating women to replace iodine losses in milk. The PRI of non-lactating women was not increased. SCF noted that the PRI increase for lactating women was based on the needs of the infant rather than the amount actually secreted in the milk.

The UK COMA (DH, 1991) did not recommend any increment for lactating women; thus the RNI was 140 µg/day as for non-lactating women.

An overview of DRVs for iodine for pregnant and lactating women is presented in Table 3.

**Table 3:** Overview of Dietary Reference Values for iodine for pregnant and lactating women

	<b>D-A-CH (2013)</b>	<b>WHO/FAO (2004)</b>	<b>NNR (2012)</b>	<b>Afssa (2001)</b>	<b>IOM (2001)</b>	<b>SCF (1993)</b>	<b>DH (1991)</b>
Pregnancy	230 µg/day (Germany, Austria), 200 µg/day (Switzerland)	200 µg/day, i.e. 3.5 µg/kg per day	175 µg/day	200 µg/day	220 µg/day	+0, i.e. 130 µg/day	+0, i.e. 140 µg/day
Lactation	260 µg/day (Germany, Austria), 200 µg/day (Switzerland)	200 µg/day, i.e. 3.5 µg/kg per day	200 µg/day	200 µg/day	290 µg/day	160 µg/day	+0, i.e. 140 µg/day

## 5. Criteria on which to base Dietary Reference Values

From the data on biomarkers of intake and status (Section 2.4), the Panel concludes that these markers change with iodine intake, but cannot be used as such and in isolation as a basis for setting DRVs for iodine. Other possible criteria include physiological criteria (such as balance studies, iodine accumulation in the thyroid and iodine requirement for thyroid hormone synthesis) or health consequences of iodine intake.

### 5.1. Iodine balance

Several balance studies are available in adults (Cole and Curtis, 1935; Vought and London, 1964; Harrison et al., 1965; Malamos et al., 1967; Vought and London, 1967; Harrison, 1968), as well as some in children (Malvaux et al., 1969; Ares et al., 2008) and pregnant women (Dworkin et al., 1966).

Balance studies are based on the assumption that a healthy subject on an adequate diet maintains equilibrium or a null balance between nutrient intakes and nutrient losses; at this null balance, the intake perfectly matches the requirement corresponding to the given physiological state of the individual. When intakes exceed losses (positive balance), there is nutrient accretion that may be attributable to growth or to weight gain, anabolism or repletion of stores; when losses exceed intakes (negative balance), nutrient stores are progressively depleted resulting, in the medium-term, in biological signs and, in the long term, in clinical symptoms of deficiency. When performed at different levels of intakes, balance studies enable the quantification of basal (or obligatory) losses (i.e. losses that occur with zero intake) by regression to zero. In addition to numerous methodological concerns about the accuracy and precision in the determinations of intakes and losses (Baer et al., 1999), the

validity of balance studies for addressing requirements has been questioned; they might possibly reflect only either adaptive changes before reaching a new steady-state (Young, 1986) or reflect only the conditions for maintenance of nutrient stores in the context of a given diet (Mertz, 1987). The relevance of this actual pool size for health remains to be established for each nutrient.

In the case of iodine, these methodological and conceptual limitations are of particular concern for a number of reasons: the iodine content of foods is highly variable resulting in large day-to-day variation, i.e. day-to-day differences of 10 to 90 times (Vought and London, 1964; Malamos et al., 1967); the pre-study status is often not precisely reported, limiting the possibility of extrapolation to habitual intake in many European countries; high pre-study habitual intakes may lead to overestimate basal losses; sweat losses are generally not taken into account; and the duration of studies is often too short for iodine status to reach a new equilibrium owing to thyroid regulation. In addition, in the absence of measurement of specific markers of thyroid function, it is difficult to relate results of balance studies to thyroid status.

The Panel notes that negative balances are observed in most of the studies in euthyroid subjects, who, despite a low intake, do not display goitre. The Panel also notes that the results of balance studies are highly variable and that balances may be null at very different levels of intakes. The Panel considers that balance studies performed in countries with a higher habitual iodine intake compared with most European countries are difficult to extrapolate to the European context. Taking into account the limitations of balance studies, especially in the case of iodine, the Panel concludes that iodine balance studies cannot be used for setting DRVs, although some of their results may contribute to informing other choices for setting DRVs for iodine.

## 5.2. Iodine accumulation in the thyroid

To set the EAR in adults, IOM (2001) used the results from two studies on the thyroidal radioiodine accumulation in euthyroid adults (Fisher and Oddie, 1969b, 1969a).

In the first study (Fisher and Oddie, 1969b), 21 healthy euthyroids adults were given radio-labelled iodine ( $^{131}\text{I}$ ) intravenously. Using a complex study design, mean UI excretion was measured as 411  $\mu\text{g/day}$ , mean thyroid accumulation was 96.5  $\mu\text{g/day}$  and mean thyroid pool size was 14.6 mg. In the second study (Fisher and Oddie, 1969a), similar measurements were conducted in 274 euthyroid US subjects. The (geometric) mean UI excretion was 281  $\mu\text{g/day}$  and the mean thyroid iodine accumulation was 91.2  $\mu\text{g/day}$ . There was a correlation between thyroid iodine accumulation and iodine intakes estimated as UI excretion; the two parameters were positively correlated and the association is described by the following equation (correlation coefficient  $r = 0.64$ ):

$$\log(\text{accumulation } [\mu\text{g/day}]) = 0.2456 + 0.7001 \times \log(\text{UI excretion } [\mu\text{g/day}])$$

Similar to medium-term iodine accumulation, short-term iodine capture by the thyroid is down-regulated along with increasing intakes (generally assessed through UI) and reaches a plateau for intakes above 80–100  $\mu\text{g/day}$  (Bernard et al., 1970; Hooper et al., 1980). In school children, iodine uptake by the thyroid gland was reported to decrease with increasing iodine intake, reaching a plateau at around 20 % (Tovar et al., 1969) or 30 % (Follis et al., 1962) of the administered dose of above 60–80  $\mu\text{g/day}$  calculated from UI excretion. In Europe, down-regulation of iodine uptake by the thyroid has also been documented (Milakovic et al., 2006): iodine uptake in the year 2000 was around 14–30 % (median 21 %) in adults aged 60–65 years having spent their adult lives in a situation of iodine adequacy (UI in 2000: 190  $\mu\text{g/L}$ ), whereas the uptake was higher 50 years earlier (median uptake 31 %, range 10–70 %).

The Panel notes that the average iodine accumulation by the thyroid obtained from the two studies of Fisher and Oddie (1969b, 1969a) was measured at an average UI excretion of about 410 and 280  $\mu\text{g/day}$ , respectively; therefore, these results on iodine accumulation do not reflect the European



situation. The Panel concludes that the values of 96.5 and 91.2 µg/day for mean iodine accumulation cannot be used for deriving DRVs for the European context.

### 5.3. Iodine requirement for thyroid hormone synthesis in euthyroid adults

The major part of iodine is released from the thyroid in the form of T4. The production of T4 has been measured in several studies with healthy euthyroid subjects: it was  $88.5 \pm 11.5$  µg/day in eight subjects (Nicoloff et al., 1972),  $102 \pm 4.9$  µg/day in 10 subjects (Chopra, 1976), 77 µg/day (range 66–110) in eight subjects (Kirkegaard et al., 1990) and 75.5 µg/day (range 50–103) in 14 subjects (Bregengard et al., 1987). These hormone production values would require 49–66 µg of available iodine.

The production of T3 in healthy euthyroid subjects is lower; values of  $27.6 \pm 3.99$  µg/day (Nicoloff et al., 1972),  $33.5 \pm 3.7$  µg/day (Chopra, 1976), 20 µg/day (Bregengard et al., 1987), 23 µg/day (Cardoso and Rosenthal, 1987), 20 µg/day (Faber et al., 1988), 24.2 µg/day (Gavin et al., 1977) and 34.6 µg/day (24.4–41.2 µg/day) (Kirkegaard et al., 1990) have been reported. The range of average total T3 production therefore would require 20–35 µg available iodine/day, but T3 production inside the thyroid gland only accounts for around 20 % of total T3 production, corresponding to 4–7 µg/day of T3 produced in the thyroid gland or to approximately 2–4 µg of iodine needed to be incorporated.

The Panel concludes that thyroid hormone production in adult euthyroid subjects would require 50–70 µg/day of iodine, to be taken up by the thyroid or released from the thyroid store. According to the equation developed by Fisher and Oddie (1969a, 1969b) (see Section 5.2), the average daily requirement for thyroid hormone synthesis of 60 µg iodine is associated with an intake leading to a calculated UI excretion of 155 µg/day.

### 5.4. Factorial approach in adults

The main factor driving iodine requirements is the iodine needed by the thyroid to produce hormones maintaining an euthyroid state and to ensure an adequate level of iodine stored in the thyroid, to which basal losses from urine, faeces and sweat should be added. In addition, transfer to the fetus and secretion in human milk need to be considered in pregnant and lactating women, respectively.

As noted in the previous section, thyroid hormone production requires 50–70 µg of iodine/day.

Faecal losses comprise unabsorbed iodine from ingested iodine (taken into account in the figure of 92 % for absorption efficiency), unabsorbed iodine from the saliva cycle (6 µg/hour in the saliva for usual intakes meeting current recommendations, assuming 92 % absorption efficiency) and undegraded hormones and different metabolites (for which iodine absorption is generally around 50 %). Faecal losses are highly variable from day to day, with most values being between 10 and 30 µg/day in the study by Vought and London (1964); a median value of 27 µg/day provided by this study may be assumed in the situation of iodine sufficiency.

Urinary losses can adapt to the level of intake within weeks or months (the actual duration depending on the initial iodine status) and, in a steady state, are considered to reflect intake. The Panel notes that the value of 57 µg considered as basal UI excretion by IOM (2001) (obtained by regression to a null intake by Vought and London (1967)) was determined in a population with relatively high iodine intakes (more than adequate according to the terminology of WHO/FAO (2004)). Similarly, basal losses in faeces and urine from the data of Vought and London (1964) probably also represent an overestimation but, being lower and obtained in free-living conditions, they are possibly more adapted to the European situation; in this study of iodine balance, the intercept of losses (urinary + faecal) for a null dietary intake is  $41.1 \pm 47.5$  µg/day for subjects on a wide range of dietary intakes (56–729 µg/day; 50 % of the subjects had iodine intakes above 200 µg/day). The Panel notes that this value was obtained in a population of adults and children.

From the limited number of available data (see Section 2.3.6.3), sweat iodine concentration is relatively constant on a wide range of intakes. At usual iodine intakes, losses in sweat may be around 20 µg/day, assuming an iodine concentration of sweat of 37 µg/L and a sweat volume of 0.5 L/day (Shirreffs and Maughan, 2005; Subudhi et al., 2005).

Assuming a demand of 60 µg/day for thyroid hormone production (40 µg for the sum of urinary and faecal losses, 20 µg for sweat losses) and an absorption efficiency of 92 %, an intake of 130 µg/day would be required to cover the losses and provide iodine for thyroid hormone production. Estimations stem from small-scale studies that indicate rather high CVs (e.g. 13–41 % for hormone production in two studies with 18 subjects (Nicoloff et al., 1972; Chopra, 1976), 18–27 % for sweat losses in two studies with 17 subjects (Suzuki and Tamura, 1985; Mao et al., 2001)).

The Panel concludes that the factorial approach, based on insufficient evidence on the size of iodine basal losses, and subject to many uncertainties related to the values of the CV and to the extrapolation of the results to the conditions of habitual iodine intakes in Europe, is not well suited for the setting of DRVs for iodine for adults in the EU, although it can provide some support to other approaches.

## 5.5. Iodine intake and health consequences

Iodine deficiency or excess has been linked to various clinical outcomes such as goitre, cognitive function, thyroid cancer or sub-clinical and overt thyroid disorders. At a population level, the association of thyroid disorders with iodine intakes appears to be U-shaped and the range for the lowest prevalence of thyroid disorders could be relatively narrow (Laurberg et al., 2010).


### 5.5.1. Goitre

Thyroid volume has been recognised as an integrative marker of medium- to long-term iodine status at the population level (see Section 2.4.2.3).

In observational studies, goitre prevalence has been associated with UI excretion. Ascoli and Arroyave (1970) measured UI excretion (µg/day) and thyroid size by palpation in people living in 186 rural localities in Central America between 1965 and 1967. Presence or absence of goitre was assessed using WHO criteria. In each locality, members of approximately 20 randomly selected families were investigated. A total of 21 611 people from 3 712 families were investigated for goitre and the concentrations of iodine and creatinine were measured in a late morning spot urine sample in 3 181 randomly chosen participants. The daily UI excretion was estimated from iodine and creatinine concentrations using an equation correcting for body weight and age- and sex-dependent differences in 24-hour urinary creatinine excretion; the Panel notes that the use of such an equation introduces some uncertainty in the precision and accuracy of the values of daily UI excretion. Goitre prevalence was inversely associated with UI excretion following a sigmoidal curve and, above a UI excretion of 100 µg/day, the prevalence of goitre was below 10 % (the level used to define endemic goitre) in all but one locality. However, the authors noted that, in a population excreting more than 60 µg/day, goitre was rare. For a UI excretion below 100 µg/day, the disparity in goitre frequency with apparently identical iodine intakes as observed in this study has been explained by other dietary factors (irregular iodine intake, intakes of other essential nutrients, goitrogen intakes) and genetic factors (Laurberg et al., 2010). Delange has pointed out that the threshold of UI excretion of 100 µg/day is also supported by data on 24-hour <sup>131</sup>I uptake by the thyroid as well as a thyroidal organic iodine content within the limits of normal, i.e. 10–20 mg (Delange and Ermans, 1991; Delange, 1994).

During the ThyroMobil project, in 7 599 European school-aged children (6–15 years), normal thyroid volume determined in areas of iodine sufficiency was around 8 mL in 15-year-old boys and girls at the 50<sup>th</sup> percentile and 16 mL at the 97<sup>th</sup> percentile. Upper limits of normal thyroid volume were also established as a function of body surface area, calculated from measured body weights and heights (Delange et al., 1997). Goitre was defined as a thyroid volume exceeding the upper limit of normal, expressed in relation to age or body surface area. An inverse non-linear relationship was observed between median UI concentration and goitre prevalence in 57 study sites in 12 European countries and

a prevalence of goitre below 5 % was almost systematically observed in all study sites for a UI concentration above 100 µg/L (Figure 1). On the basis of the daily urine volume, it is thus possible to calculate the corresponding iodine intake for the different age groups.



**Figure 1:** Relationship between urinary iodine concentration and goitre prevalence in school-aged children (adapted from Delange et al., 1997)

Subsequently, the threshold value for classification of iodine intakes (into “sufficient” or “insufficient”) by population groups other than pregnant women was given as iodine concentration in urine, i.e. 100 µg/L (WHO/UNICEF, 2007b). However, the shift from using a UI excretion of 100 µg/day to a UI concentration of 100 µg/L, for population groups other than school children and pregnant women, as the lower threshold indicating sufficient iodine intake, resulted in an increase in the recommended iodine intake for many population groups without any real evidence that this was necessary to avoid IDD (Laurberg et al., 2007).

Ristić-Medić et al. (2013) performed several meta-analyses on the relationship between iodine intake and the risk of goitre. Owing to the diversity of measurement methods and expression of the results, as well as the limited duration of the observation/intervention periods contrasting with the time required for observing changes in goitre prevalence in a population (Laurberg et al., 2010), the Panel considers that the pooling of these data in a meta-analysis does not provide a dose-response curve that could be used for deriving DRVs for iodine.

In 65 infants born at term, there was an inverse polynomial relationship between thyroid volumes three months after birth and UI concentrations; infants with a UI concentration above about 150 µg/L had thyroid volumes below 1 mL, whereas thyroid volumes of some infants with lower UI concentrations were up to about 4 mL. The upper limit of normal thyroid volumes is, however, unclear in this age group (Böhles et al., 1993). Chanoine et al. (1991) observed a median thyroid volume of 0.76 mL in 85 euthyroid neonates in an area with a median UI concentration of 97 µg/L and a volume of 1.25 mL for the 90<sup>th</sup> percentile.

The Panel considers that the prevalence of thyroid volume enlargement in a population can be used to define a threshold of UI excretion (adults) and UI concentration (children) above which the prevalence of abnormal values for thyroid volume is minimised. The Panel notes that the slow modification of

this parameter provides a valuable medium- to long-term health outcome in relation to usual iodine intakes at the population level. In comparison with other approaches, where sources of variability and uncertainty are not fully identified and/or controlled for, the major source of uncertainty originates from the estimation of a daily iodine intake from the UI excretion or concentration.

### 5.5.2. Cognitive function in children

The role of iodine insufficiency in the impaired development of cognitive function, with the most severe form expressed as cretinism (see Section 2.2.2), was recognised a long time ago, and was followed by therapeutic measures using iodine (Anonymous, 1869). Mass prevention of cretinism in areas of severe iodine deficiency has shown that the most efficient prevention was achieved by improving maternal iodine status before pregnancy (Pharoah et al., 1971).

Ristić-Medić et al. (2013) undertook a systematic review of the literature for studies relating iodine intake to cognitive function in children with goitre and/or iodine deficiency; 13 studies (five randomised controlled trials (RCTs), four cross-sectional studies and four nested case-control studies) were selected. In most intervention studies, children aged between 1 and 14 years were given a single dose of iodised oil (400–540 mg), with a follow-up of 4–22 months. Only one study used daily doses of 150 µg/day as tablets of potassium iodide versus placebo, but the intervention lasted 28 weeks and was therefore too short and not relevant for this outcome. Different tests for evaluation of cognitive function were used. The Panel notes that the results from the included RCTs were inconsistent, probably as a result of heterogeneity of the studies and high or moderate risk of bias in most of the included studies. The number of included studies for moderate iodine deficiency was generally small and the studies were methodologically weak. Observational studies in severely iodine-deficient groups (median UI concentration < 20 µg/L) indicated a strong relationship between iodine intake or status and cognitive impairment. Data in infants were unavailable.

The Panel concludes that data on iodine intake and cognitive function cannot be used to derive DRVs for iodine.

### 5.5.3. Cancer

According to WCRF/AICR (2007), iodine deficiency (via higher serum TSH concentrations) is a “probable” cause and iodine excess is a “possible” cause of thyroid cancer.

The Panel considers that data on iodine deficiency and cancer cannot be used to derive DRVs for iodine.

### 5.5.4. Sub-clinical thyroid diseases

The availability of precise and accurate methods with a high analytical sensitivity allowed the recognition of the existence of sub-clinical thyroid diseases (SCTD) characterised by serum concentrations of thyroid hormones within the normal range contrasting with the presence of abnormal TSH concentrations; in sub-clinical hypothyroidism, TSH increases to above 5 mU/L, whereas in sub-clinical hyperthyroidism it decreases to below 0.3 mU/L. The prevalence of sub-clinical hypothyroidism is higher (up to above 15 %) in groups of older adults in most of the surveys addressing this issue. The causes of this high prevalence in the elderly are multiple, and include high iodine intakes: SCTDs are more prevalent (up to five times) in areas of high iodine intake compared with areas of low intake (Biondi and Cooper, 2008). Although sub-clinical hypothyroidism may be transient in older adults, the risk of evolving to overt hypothyroidism is important in SCTD-affected subjects with the highest concentrations of TSH (> 10 mU/L) (Somwaru et al., 2012). SCTD might be associated with an increased risk of cardiovascular disease and mortality (Rodondi et al., 2010), an increased risk of depression (Chueire et al., 2007) or of impaired functional mobility (Simonsick et al., 2009).

The Panel considers that data on iodine intake and prevalence of SCTD are insufficient to support the necessity for deriving DRVs specific for older adults.



## 5.6. Additional iodine requirement for pregnancy

Recent studies of iodine in pregnancy have focused on the relationship of thyroid function (assessed through the determination of maternal hormone concentrations and autoantibodies) to various clinical outcomes rather than on the relationship of these outcomes with iodine intakes and/or status (Gunnarsdottir and Dahl, 2012). In the absence of a clear dose-response relationship between obstetrical or paediatric outcomes and iodine intakes, the requirement during pregnancy may be derived by a factorial approach, taking into account extra needs owing to modification of iodine metabolism during pregnancy and to the development of the fetal thyroid and fetal hormone synthesis, which should be added to the pre-pregnancy requirement. The results of supplementation studies may provide additional information. The definition of reference values implies that iodine status before pregnancy is adequate.

### 5.6.1. Thyroid status, urinary iodine excretion and clinical outcomes

The prevention of cretinism in areas of severe iodine deficiency is more efficient before conception than during pregnancy (Pharoah et al., 1971), though an increase in iodine intake during the first and second trimester can still have a beneficial impact, contrary to an increase of iodine intake only during the last trimester (Cao et al., 1994).

The relationship between iodine intake of pregnant women (generally assessed through UI excretion) and clinical outcomes, such as maternal thyroid function or infants' neurobehavioral impairment and being born small for gestational age, has been investigated in several studies (Alvarez-Pedrerol et al., 2009; Henrichs et al., 2010; Costeira et al., 2011; Karagiannis et al., 2011; van Mil et al., 2012; Bath et al., 2013a; Hynes et al., 2013). The Panel notes that available studies are mostly observational and that most of them do not provide data on pre-pregnancy iodine status. The Panel considers that the information available on the relationship between iodine intake or status of pregnant women and these clinical outcomes cannot be used for setting DRVs for pregnancy.

### 5.6.2. Supplementation studies during pregnancy

It is well established that iodine supplementation before or during early pregnancy has an impact on cognitive function in the offspring in areas of severe or moderate iodine deficiency (Zhou et al., 2013), although the impact of this public health measure in areas of mild or marginal deficiency, as it is still present in Europe, remains to be studied by high-quality intervention studies (Bath et al., 2013b; Rebagliato et al., 2013).

Iodine supplementation during pregnancy is generally effective at minimising an increase in maternal thyroid size in iodine-deficient areas (Pedersen et al., 1993; Glinoer et al., 1995; Berghout and Wiersinga, 1998; Antonangeli et al., 2002; Zimmermann and Delange, 2004; Zimmermann, 2009; Rebagliato et al., 2010; Zimmermann, 2012). However, these studies usually lack important information, such as the iodine status before pregnancy or the total iodine intake of pregnant women. Therefore, the Panel concludes that results from the available supplementation studies cannot be used for setting a DRV for iodine for pregnant women.

### 5.6.3. Additional requirement owing to modifications of maternal iodine metabolism

Maternal thyroid hormone production increases during pregnancy owing to several physiological adaptations and this is reflected in the need of women on thyroid hormone substitution therapy to increase by 40–50 % (average 47 %) the dose of thyroxin to maintain their normal pre-pregnancy concentrations of T4 and TSH during pregnancy (Mandel et al., 1990; Alexander et al., 2004). In the study by Alexander et al. (2004), the average thyroxin dose was 133 µg/day; thus, using the above data, the increase may be calculated ( $133 \mu\text{g/day} \times 47\%$ ) as 63 µg/day. In the study by Kaplan (1992), the extra need for exogenous thyroxin during pregnancy was 41 µg for women with TSH concentrations below 10 mU/L. Based on these studies, the study by Yassa et al. (2010) used increases in thyroxine doses of 29 % or 33 % and showed that only 3 women out of 48 did not maintain a serum

1064 TSH concentration below the upper bound value of 5 mU/L, and thus confirming the validity of the  
1065 previous determinations.

1066 The Panel considers that, on the basis of an extra need of exogenous thyroxine of 40–60 µg/day in  
1067 these patients with an absorption efficiency of around 75 % for oral thyroxine, endogenous production  
1068 of T4 is estimated to be increased by around 37 µg/day, corresponding to an additional iodine demand  
1069 of 25 µg/day for hormone synthesis in the thyroid.

#### 1070 **5.6.4. Additional requirement owing to the development of the fetus, placenta and amniotic** 1071 **fluid**

1072 At the beginning of pregnancy, maternal T4 is the only source of hormone for the fetus, and this  
1073 hormone is required at a very early fetal age for normal corticogenesis in the brain (Morreale de  
1074 Escobar et al., 2004). Thereafter, iodine supply to the mother and its transfer to the fetus must be  
1075 adequate to prevent fetal goitre formation (Glinoe et al., 1995), inducing a growing need of iodine for  
1076 hormone synthesis by the fetal thyroid gland and for storage in the fetal thyroid, placenta and amniotic  
1077 fluid.

##### 1078 5.6.4.1. Fetal and neonatal thyroid

1079 The interpretation of studies on neonatal iodine status should take into account the iodine status of the  
1080 mother and the time elapsed between birth and the biological determinations in the newborn; these  
1081 characteristics are not always reported and might explain the very different figures provided in the  
1082 literature. For a similar gestational age (around 30 weeks), thyroid iodine content increases from  
1083 60 µg/g (at around 10 hours after birth) to 93 µg/g (at around 30 hours) and 263 µg/g (after more than  
1084 10 days) (Etling, 1977); the impact of postnatal age on the characteristics of the neonatal thyroid has  
1085 been confirmed by Savin et al. (2003).

1086 Costa et al. (1986) measured a thyroid weight of 0.37 g at week 23 and 0.71 g at week 26 that  
1087 remained practically constant up to term (0.74 g), with an iodine content of 60 µg/g thyroid at term  
1088 (maximum of 123 µg/g) for a group of 52 newborns having a UI concentration of  $64 \pm 29$  µg/L (the  
1089 corresponding concentration for the mothers being  $74 \pm 37$  µg/L). For late-preterm and term newborns  
1090 of  $2.5 \pm 0.6$  kg body weight, Savin et al. (2003) found a thyroid weight of  $0.93 \pm 0.4$  g and an iodine  
1091 content of  $95.5 \pm 34.4$  µg/g. Higher iodine contents in the thyroid have been reported for countries  
1092 with more than adequate maternal iodine intakes, for example around 300 µg in Toronto (UI excretion  
1093 in adults being 600–800 µg/day) (Delange and Ermans, 1991).

1094 Fetal hormonal synthesis becomes significant at the 12<sup>th</sup> week of gestation and increases linearly with  
1095 fetal size up to the 24<sup>th</sup> gestational week when the postnatal total T4 concentration of around 60 µg/L  
1096 is reached (Greenberg et al., 1970; Thorpe-Beeston et al., 1991). The theoretical turnover of the  
1097 intrathyroidal T4 pool in preterm infants born after six months of gestation has been determined (early  
1098 after birth) to be 1–10 times per day (van den Hove et al., 1999) when assuming that a thyroxine dose  
1099 of 10 µg/kg body weight per day is needed in hypothyroid newborns; this turnover rate is decreased by  
1100 thyroxine. However, a high turnover is apparent only for newborns in countries with low iodine status  
1101 (Delange and Ermans, 1991) and would most likely correspond to the postnatal requirement. The  
1102 Panel considers that the impact of the high turnover of the intrathyroidal T4 pool measured in  
1103 newborns in a low iodine context on the fetal requirement in iodine-adequate conditions is not known.

1104 The Panel also notes that a thyroid iodine content of 100–300 µg at birth, accumulated during the two  
1105 last trimesters, would approximately correspond to a net iodine transfer of 1–2 µg/day to the fetal  
1106 thyroid. Evans et al. (1967) determined that iodine transfer to the fetal thyroid is starting at around  
1107 three months of gestation and accounts for 1 % of the dose ingested by the mother at six months and  
1108 for 2 % at nine months. Iodine uptake by the thyroid reached a maximum of 5 % per gram of thyroid  
1109 tissue at six months of gestation, which suggests that iodine turnover of the fetal thyroid is rather low.  
1110 The iodine uptake by the thyroid of the mothers was in the range of 10–35 %, indicating a near-to-

adequate iodine status. Contrary to some other mammals, the human fetus does not concentrate iodide (Rayburn et al., 2008).

In fetal blood, T4 is the prominent form. According to Thorpe-Beeston et al. (1991), total T4 is on average 77 µg/L in the fetus at 36 weeks of gestation; the postnatal serum total T4 concentration of a term newborn is around 120 µg/L, corresponding to a total amount of organic iodine in serum of around 10–15 µg,<sup>7</sup> with part of this iodine (up to 40 %, Vulsma et al. (1989)) being represented by maternal hormone, which has already been considered in Section 5.6.3.

#### 5.6.4.2. Placenta and amniotic fluid

The placenta traps maternal serum iodide through the Na/I symporter, the expression of which remains constant during pregnancy, suggesting no specific adaptation through this symporter (Di Cosmo et al., 2006). The placenta has an iodine content of 30 ng/g compared with the content of below 2 ng/g for the myometrium. Uptake and storage by the placenta are dependent on iodine intake (Burns et al., 2011b); therefore, a total storage capacity of around 18 to 100 µg iodine could play a significant role in fetal iodine economy (Burns et al., 2011a).

Amniotic fluid also contains iodine and its concentration is correlated with maternal UI excretion, although this relationship is weak ( $r = 0.11$ ); the concentration of iodine in amniotic fluid has been reported to be around 15 µg/L in an area with median UI concentrations of 118 µg/L and to be independent of the ingestion of iodine supplements (Garcia-Fuentes et al., 2008). Considering a volume of amniotic fluid around one litre at 32–36 weeks of gestation (Queenan et al., 1972), the impact on the maternal requirement for iodine can be considered as negligible.

#### 5.6.5. Conclusions on additional iodine requirement for pregnancy

The total amount of iodine deposited in the placenta (18–100 µg), amniotic fluid (15 µg), fetal thyroid (100–300 µg) and fetal blood (10 µg) is very low when related to the whole pregnancy (equivalent to a net transfer of 1 µg/day). The main additional requirement seems, therefore, to be the result of the increased synthesis of thyroid hormones by the mother, corresponding to a need for an additional iodine capture by the thyroid of 25 µg/day. Assuming that the equation of Fisher and Oddie (1969a) derived in non-pregnant adults remains valid in pregnancy (see Section 5.2), this amount may be accumulated in the thyroid by an additional iodine intake of 44 µg/day. In addition, the iodine needed for fetal synthesis of thyroid hormones, which is likely to be low considering the limited iodine transfer to the fetal thyroid gland of around 2–4 µg/day (Evans et al., 1967), leads to a total additional iodine intake rounded to 50 µg/day.

The Panel concludes that the many physiological regulations taking place during pregnancy lead to an increase in iodine requirement during gestation of around 50 µg/day, provided that thyroid status and iodine stores before pregnancy are adequate.

#### 5.7. Additional iodine requirement for lactation

Breast milk iodine concentrations are more a reflection of maternal iodine intake than of the infant's needs (see Section 2.3.5.4).

Azizi and Smyth (2009) reported a linear relationship between breast milk iodine concentration and maternal UI excretion in the range of 50–400 µg/L, although the correlation coefficient in a cohort of 100 lactating women was relatively low ( $r = 0.44$ ). For example, from the relationship provided in this study, an iodine concentration above 100 µg/L in breast milk can be achieved with a UI of 100–200 µg/L; the slope of the curve that links breast milk concentration to UI concentration is low (around 0.2, deduced from the figure). In Danish lactating women either taking ( $n = 60$ ) or not taking

<sup>7</sup>  $3.5 \text{ kg} \times 12 \% \text{ equals } 0.42 \text{ kg}$  or about 420 mL, corresponding to around 210 mL of serum. Assuming a serum total T4 concentration of 120 µg/L, the amount of T4 in 210 mL of serum is 16 µg. As the iodine content in T4 is 65 %, a value of 10.5 µg iodine can be calculated.



1154 (n = 67) iodine supplements, median iodine concentration in mature breast milk was 112 µg/L in  
 1155 supplemented women with a median UI excretion of 87 µg/day and it was 72 µg/L in unsupplemented  
 1156 women with a UI excretion of 60 µg/day (Andersen et al., 2013).

1157 In conditions of adequate iodine stores in the thyroid (10–15 mg), iodine stores would theoretically  
 1158 allow several months of iodine secretion in milk. In conditions of maternal iodine deficiency, the  
 1159 iodine secretion in milk can lead to thyroid stimulation in the mother as evidenced by modifications of  
 1160 thyroid markers (TSH, thyroid hormones, thyroglobulin, thyroid volume). Without changes in iodine  
 1161 intake, these modifications can be reversed 6 to 10 months after delivery, although the reversibility of  
 1162 thyroid volume may only be partial within this timeframe (Glinioer et al., 1992; Eltom et al., 2000).  
 1163 The Panel notes the existence of large physiological iodine stores in conditions of adequate iodine  
 1164 status before pregnancy and lactation.

## 1165 6. Data on which to base Dietary Reference Values

1166 The Panel considers that thyroid volume/prevalence of goitre is an integrative marker of medium- to  
 1167 long-term thyroid status of a population, for which a large database collected in males and females  
 1168 with very different iodine intakes is available. Moreover, this marker is insensitive to short-term  
 1169 modifications of iodine intake, and thus eliminating many sources of variability and uncertainties  
 1170 inherent in short-term metabolic or balance studies. The Panel selected this association as the basis for  
 1171 deriving DRVs for iodine. The values obtained using other criteria appear to support this approach.  
 1172 From the data available, there is no indication that iodine requirement differs by sex.

### 1173 6.1. Adults

1174 At a population level, a UI excretion of 100 µg/day or higher is associated with a goitre prevalence of  
 1175 up to 10 % in Central America in the 1960s. During homeostasis more than 90 % of dietary iodine is  
 1176 excreted in the urine (see Section 2.3.6.1); thus, it can be calculated that a daily UI excretion of  
 1177 100 µg/day is equivalent to an iodine intake of 110 µg/day. The Panel notes that this threshold implies  
 1178 that up to 10 % of the population may still develop goitre, possibly resulting from iodine deficiency,  
 1179 and that this approach may underestimate the iodine needs of up to 10 % of the population.

1180 For the population of school-aged children, a UI concentration of 100 µg/L or higher has been shown  
 1181 to be associated with the lowest prevalence of goitre. Although this threshold has been established in  
 1182 school-aged children, the Panel also accepts it for adults. A UI concentration of 100 µg/L corresponds  
 1183 to an approximate iodine intake of 150 µg/day in adults (Laurberg et al., 2007).

1184 This is based on an average daily urinary volume of 1.5 L, which can be achieved by the AI for water  
 1185 for adults (EFSA NDA Panel, 2010).

1186 The Panel considers that an AI for iodine for adult men and women can be set at 150 µg/day.

1187 The Panel notes that other approaches, such as the approach based on thyroid hormone production and  
 1188 the factorial approach (Sections 5.3 and 5.4), support this value.

### 1189 6.2. Infants and young children

1190 For infants below one year of age, data on goitre prevalence in relation to iodine intake or UI excretion  
 1191 or concentration are unavailable.

1192 Accepting the threshold for UI concentration of 100 µg/L (see Section 5.5.1) also for infants and  
 1193 taking into account a urinary volume of 637 mL/day based on a daily urine volume of 74.1 mL/kg  
 1194 body weight measured in 15 normal infants aged 6–12 months (Goellner et al., 1981), a necessary  
 1195 iodine intake of 70 µg/day can be calculated (see Table 4). The Panel considers that the AI for iodine  
 1196 for infants is 70 µg/day.

Accepting the threshold for UI concentration of 100 µg/L (see Section 5.5.1) also for young children and taking into account a urinary volume of 827 mL/day (average urinary volume of 69.5 mL/kg per day for children aged 12–32 months according to Goellner et al. (1981)) and a median body weight of 11.9 kg at two years of age according to WHO Multicentre Growth Reference Study Group (2006), a necessary iodine intake of 90 µg/day can be calculated (see Table 4). The Panel considers that the AI for iodine for young children is 90 µg/day.

**Table 4:** Reference body weights, urinary volume and Adequate Intake for iodine for infants and young children

Age	Average body weight (kg)	Urinary volume (mL/kg bw per day)	Urinary volume (L/day)	Calculated iodine intake (µg/day) <sup>(a)</sup>	AI (µg/day)
7–11 months	8.6 <sup>(b)</sup>	74.1	0.637	69.2	70
1–3 years	11.9 <sup>(c)</sup>	69.5 <sup>(d)</sup>	0.827	89.9	90

(a): Taking into account a threshold UI concentration of 100 µg/L and 92 % absorption efficiency according to the formula:

$$\text{Theoretical daily iodine intake (µg/day)} = (100 \text{ µg/L} \times \text{urinary volume [L/day]})/0.92.$$

(b): Mean of body weight for age at 50<sup>th</sup> percentile of male and female infants aged nine months (WHO Multicentre Growth Reference Study Group, 2006).

(c): Mean of body weight for age at 50<sup>th</sup> percentile of boys and girls aged 24 months (WHO Multicentre Growth Reference Study Group, 2006).

(d): Mean of volumes for three age groups, i.e. 80.6 mL/kg per day (12–18 months), 66.2 mL/kg per day (18–24 months) and 61.7 mL/kg per day (24–32 months) (Goellner et al., 1981).

bw, body weight.

### 6.3. Children

For children, a large study in European boys and girls aged 6–15 years found a wide range of median UI concentrations in groups living in regions with very different iodine environments (medians of UI concentrations ranging from 20 to 140 µg/L). The UI concentration at which goitre prevalence in this population was at 2–3 % was about 100 µg/L (Delange et al., 1997) (see Section 5.5.1). Taking into account urinary volume and iodine absorption efficiency, this concentration can be converted into an AI for children between 6 and 15 years of age. In the absence of data for children below six years or above 15 years of age, the same approach is chosen. Despite a large variability, the median urinary flow in this large age group is around 0.9 mL/hour per kg body weight (21.6 mL/day per kg body weight), being higher (around 1.4 mL/hour per kg body weight or 33.6 mL/day per kg body weight) for the youngest and lower (around 0.8 mL/hour per kg body weight or 19.2 mL/day per kg body weight) for the oldest (Mattsson and Lindstrom, 1995). The calculations using these urinary flows and reference body weights for European children (van Buuren et al., 2012) are shown in Table 5. Calculated daily urinary volumes are in line with 24-hour urine volumes observed in a cohort of 293 children aged 4–6 years and of 326 children aged 7–10 years (Montenegro-Bethancourt et al., 2013).

**Table 5:** Reference body weights, urinary volume and Adequate Intake for iodine for children

Age	Average body weight (kg)	Urinary flow (mL/hour per kg bw) <sup>(a)</sup>	Calculated urinary volume (L/day)	Calculated iodine intake (µg/day) <sup>(b)</sup>	AI (µg/day)
4–6 years	19.0 <sup>(c)</sup>	1.4	0.638	69.4	90 <sup>(d)</sup>
7–10 years	28.7 <sup>(e)</sup>	1.2	0.827	89.8	90
11–14 years	45.7 <sup>(f)</sup>	1.0	1.097	119.2	120
15–17 years	60.3 <sup>(g)</sup>	0.8	1.157	125.8	130

- 1230 (a): Estimated from the curve established by Mattsson and Lindstrom (1995), for ages defined in notes (e)–(g), and  
 1231 extrapolated from this curve for age five years.  
 1232 (b): Taking into account a threshold UI concentration of 100 µg/L and 92 % absorption efficiency according to the formula:  
 1233 
$$\text{Theoretical daily iodine intake (µg/day)} = (100 \text{ µg/L} \times \text{urinary volume [L/day]})/0.92.$$
  
 1234 (c): Mean of body weight at 50<sup>th</sup> percentile of boys and girls aged five years (van Buuren et al., 2012).  
 1235 (d): As there is no reason to assume that iodine needs are lower for this age group, the same AI is proposed as for the  
 1236 neighbouring age groups.  
 1237 (e): Mean of body weight at 50<sup>th</sup> percentile of boys and girls aged 8.5 years (van Buuren et al., 2012).  
 1238 (f): Mean of body weight at 50<sup>th</sup> percentile of boys and girls aged 12.5 years (van Buuren et al., 2012).  
 1239 (g): Mean of body weight at 50<sup>th</sup> percentile of boys and girls aged 16 years (van Buuren et al., 2012).  
 1240 bw, body weight.

#### 1241 **6.4. Pregnancy**

1242 The factorial approach takes into account the AI in the pre-pregnant state (based on thyroid size and  
 1243 supported by other considerations, see Section 6.1) and the additional needs owing to increased  
 1244 thyroid hormone production during pregnancy and the iodine uptake by the fetus, placenta and  
 1245 amniotic fluid, which amount to 50 µg/day (see Sections 5.6.3 to 5.6.5). The Panel proposes to set an  
 1246 AI at 200 µg/day.

#### 1247 **6.5. Lactation**

1248 The Panel notes that iodine concentrations in breast milk of European women differ widely. The Panel  
 1249 also notes that the SCF (2003) considered daily iodine losses with breast milk of 60 µg/day, assuming  
 1250 an average iodine concentration of 75 µg/L and a breast milk intake of 0.8 L/day, and that one study  
 1251 showed that women with a median UI excretion of 87 µg/day, and thus below the threshold of  
 1252 100 µg/day, had a median breast milk iodine concentration of 112 µg/L (Andersen et al., 2013).  
 1253 Assuming an average milk volume of 0.8 L/day (Butte and King, 2002; FAO/WHO/UNU, 2004;  
 1254 EFSA NDA Panel, 2009), iodine losses with breast milk in these women would amount to 90 µg/day.  
 1255 The Panel notes the existence of large iodine stores in conditions of adequate iodine status before  
 1256 pregnancy and lactation and considers that a full compensation of the transitory loss of iodine secreted  
 1257 in breast milk is not justified for the derivation of DRVs for iodine for lactating women. The Panel  
 1258 therefore considers that the AI for lactating women is the same as for pregnant women (200 µg/day).

1259

## CONCLUSIONS AND RECOMMENDATIONS

### CONCLUSIONS

The Panel concluded that there is insufficient evidence to derive an AR and a PRI for iodine. Data on the relationship between iodine intakes and UI excretion in population groups without signs of thyroid dysfunction evidenced by a minimal prevalence of goitre were used to set an AI (Table 6). For adults and children, the AI is based on iodine intakes ensuring a UI concentration which has been associated with the lowest prevalence of goitre in school-aged children ( $\geq 100 \mu\text{g/L}$ ). For children, age-specific urinary volumes and absorption efficiency of dietary iodine were taken into account to calculate the AI. It was considered unnecessary to give sex-specific values. An AI is also proposed for infants and young children based on the UI concentration which has been associated with the lowest prevalence of goitre in school-aged children. For pregnancy, a factorial approach was used, assuming that iodine intake is adequate before pregnancy. For lactation, the existence of large iodine stores in conditions of adequate iodine status was noted and it was considered that a full compensation of the transitory loss of iodine secreted in breast milk is not justified. Therefore, the same AI as in pregnant women was set.

**Table 6:** Summary of Adequate Intakes for iodine

Age	Adequate Intake ( $\mu\text{g/day}$ )
7–11 months	70
1–3 years	90
4–6 years	90
7–10 years	90
11–14 years	120
15–17 years	130
$\geq 18$ years	150
Pregnancy	200
Lactation	200

### RECOMMENDATIONS FOR RESEARCH

The Panel suggests that studies be undertaken on iodine requirements in all population groups, especially in pregnancy, lactation and infancy, relating iodine intakes to thyroid morphology and function and health outcomes more directly.

## REFERENCES

- Aboul-Khair SA, Crooks J, Turnbull AC and Hytten FE, 1964. The physiological changes in thyroid function during pregnancy. *Clinical Science*, 27, 195-207.
- Afssa (Agence française de sécurité sanitaire des aliments), 2001. Apports nutritionnels conseillés pour la population française. Editions Tec&Doc, Paris, France, 605 pp.
- Ain KB, Mori Y and Refetoff S, 1987. Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation: a mechanism for estrogen-induced elevation of serum TBG concentration. *Journal of Clinical Endocrinology and Metabolism*, 65, 689-696.
- Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA and Larsen PR, 2004. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. *New England Journal of Medicine*, 351, 241-249.
- Alfred Rusescu Institute for Mother and Child Care, 2005. Nutritional status of pregnant women, children under 5 years old and schoolchildren aged 6-7 years. Romania. A study conducted in cooperation and with the support of the UNICEF Representative Office in Romania. 20 pp.
- Allain P, Berre S, Krari N, Laine-Cessac P, Le Bouil A, Barbot N, Rohmer V and Bigorgne JC, 1993. Use of plasma iodine assay for diagnosing thyroid disorders. *Journal of Clinical Pathology*, 46, 453-455.
- Alvarez-Pedrerol M, Guxens M, Mendez M, Canet Y, Martorell R, Espada M, Plana E, Rebagliato M and Sunyer J, 2009. Iodine levels and thyroid hormones in healthy pregnant women and birth weight of their offspring. *European Journal of Endocrinology*, 160, 423-429.
- Andersen S, Pedersen KM, Iversen F, Terpling S, Gustenhoff P, Petersen SB and Laurberg P, 2008a. Naturally occurring iodine in humic substances in drinking water in Denmark is bioavailable and determines population iodine intake. *British Journal of Nutrition*, 99, 319-325.
- Andersen S, Karmisholt J, Pedersen KM and Laurberg P, 2008b. Reliability of studies of iodine intake and recommendations for number of samples in groups and in individuals. *British Journal of Nutrition*, 99, 813-818.
- Andersen SL, Moller M and Laurberg P, 2013. Iodine concentrations in milk and in urine during breastfeeding are differently affected by maternal fluid intake. *Thyroid* Nov 8. [Epub ahead of print].
- Andersson M, Berg G, Eggertsen R, Filipsson H, Gramatkovski E, Hansson M, Hulthen L, Milakovic M and Nystrom E, 2009. Adequate iodine nutrition in Sweden: a cross-sectional national study of urinary iodine concentration in school-age children. *European Journal of Clinical Nutrition*, 63, 828-834.
- Andersson M, Karumbunathan V and Zimmermann MB, 2012. Global iodine status in 2011 and trends over the past decade. *Journal of Nutrition*, 142, 744-750.
- Anonymous, 1869. Goitre en Savoie. *Journal de la Société de Statistique de Paris*, 10.
- Antonangeli L, Maccherini D, Cavaliere R, Di Giulio C, Reinhardt B, Pinchera A and Aghini-Lombardi F, 2002. Comparison of two different doses of iodide in the prevention of gestational goiter in marginal iodine deficiency: a longitudinal study. *European Journal of Endocrinology*, 147, 29-34.
- Aquaron R, Delange F, Marchal P, Lognone V and Ninane L, 2002. Bioavailability of seaweed iodine in human beings. *Cellular and Molecular Biology*, 48, 563-569.
- Ares S, Quero J and de Escobar GM, 2008. Iodine balance, iatrogenic excess, and thyroid dysfunction in premature newborns. *Seminars in Perinatology*, 32, 407-412.
- Ascoli W and Arroyave G, 1970. Epidemiología del bocio endémico en Centro América. Relación entre prevalencia y excreción urinaria de yodo. *Archivos Latinoamericanos de Nutricion*, 20, 13 pp.

- 1327 Azizi F and Smyth P, 2009. Breastfeeding and maternal and infant iodine nutrition. *Clinical*  
1328 *Endocrinology*, 70, 803-809.
- 1329 Bader N, Moller U, Leiterer M, Franke K and Jahreis G, 2005. Pilot study: tendency of increasing  
1330 iodine content in human milk and cow's milk. *Experimental and Clinical Endocrinology and*  
1331 *Diabetes*, 113, 8-12.
- 1332 Baer DJ, Fong AK, Novotny JA and Oexmann MJ, 1999. Compartmental modeling, stable isotopes  
1333 and balance studies. In: *Well-Controlled Diet Studies in Humans, A Practical Guide to Design and*  
1334 *Management*. Ed Dennis B. American Dietetic Association, Chicago, USA, pp. 238-254.
- 1335 Bath SC, Steer CD, Golding J, Emmett P and Rayman MP, 2013a. Effect of inadequate iodine status  
1336 in UK pregnant women on cognitive outcomes in their children: results from the Avon  
1337 Longitudinal Study of Parents and Children (ALSPAC). *Lancet*, 382, 331-337.
- 1338 Bath SC, Jolly KB and Rayman MP, 2013b. Iodine supplements during and after pregnancy. *JAMA*,  
1339 309, 1345.
- 1340 Berghout A and Wiersinga W, 1998. Thyroid size and thyroid function during pregnancy: an analysis.  
1341 *European Journal of Endocrinology*, 138, 536-542.
- 1342 Bernard JD, McDonald RA and Nesmith JA, 1970. New normal ranges for the radioiodine uptake  
1343 study. *Journal of Nuclear Medicine*, 11, 449-451.
- 1344 Berson SA, Yalow RS, Sorrentino J and Roswit B, 1952. The determination of thyroidal and renal  
1345 plasma I131 clearance rates as a routine diagnostic test of thyroid dysfunction. *Journal of Clinical*  
1346 *Investigation*, 31, 141-158.
- 1347 Biondi B and Cooper DS, 2008. The clinical significance of subclinical thyroid dysfunction.  
1348 *Endocrine Reviews*, 29, 76-131.
- 1349 Bittermann H, 1999. Iodine supply of German conscripts at age 17.5-21 years. Doctoral thesis,  
1350 Charité, Berlin.
- 1351 Bizhanova A and Kopp P, 2009. Minireview: The sodium-iodide symporter NIS and pendrin in iodide  
1352 homeostasis of the thyroid. *Endocrinology*, 150, 1084-1090.
- 1353 Böhles H, Aschenbrenner M, Roth M, von Loewenich V, Ball F and Usadel KH, 1993. Development  
1354 of thyroid gland volume during the first 3 months of life in breast-fed versus iodine-supplemented  
1355 and iodine-free formula-fed infants. *Clinical Investigator*, 71, 13-20.
- 1356 Bonofiglio D, Catalano S, Perri A, Baldini MP, Marsico S, Tagarelli A, Conforti D, Guido R and  
1357 Ando S, 2009. Beneficial effects of iodized salt prophylaxis on thyroid volume in an iodine  
1358 deficient area of southern Italy. *Clinical Endocrinology*, 71, 124-129.
- 1359 Bottazzo GF, 1981. Thyroid growth-blocking antibodies in autoimmune (AI) atrophic thyroiditis.  
1360 *Annales d'Endocrinologie* 42, 13A.
- 1361 Braverman LE and Utiger RD, 1991. The thyroid. A fundamental and clinical text. Lippincott  
1362 Williams & Wilkins, Philadelphia, USA, pp. 1365.
- 1363 Bregengard C, Kirkegaard C, Faber J, Poulsen S, Hasselstrom K, Siersbaek-Nielsen K and Friis T,  
1364 1987. Relationships between serum thyrotropin, serum free thyroxine (T4), and 3,5,3'-  
1365 triiodothyronine (T3) and the daily T4 and T3 production rates in euthyroid patients with  
1366 multinodular goiter. *Journal of Clinical Endocrinology and Metabolism*, 65, 258-261.
- 1367 Buchinger W, Lorenz-Wawschinek O, Semlitsch G, Langsteger W, Binter G, Bonelli RM and Eber O,  
1368 1997. Thyrotropin and thyroglobulin as an index of optimal iodine intake: correlation with iodine  
1369 excretion of 39,913 euthyroid patients. *Thyroid*, 7, 593-597.
- 1370 Burns R, O'Herlihy C and Smyth PP, 2011a. The placenta as a compensatory iodine storage organ.  
1371 *Thyroid*, 21, 541-546.



- 1372 Burns R, Azizi F, Hedayati M, Mirmiran P, O'Herlihy C and Smyth PP, 2011b. Is placental iodine  
1373 content related to dietary iodine intake? *Clinical Endocrinology*, 75, 261-264.
- 1374 Busnardo B, Nacamulli D, Frigato F, Vianello-Dri A, De Vido D, Mian C, Candiani F, Tomasella G,  
1375 Zambonin L, Piccolo M and Girelli ME, 2003. Normal values for thyroid ultrasonography, goiter  
1376 prevalence and urinary iodine concentration in schoolchildren of the Veneto Region, Italy. *Journal*  
1377 *of Endocrinological Investigation*, 26, 991-996.
- 1378 Butte N and King JC, 2002. Energy requirements during pregnancy and lactation. Energy background  
1379 paper prepared for the joint FAO/WHO/UNU Consultation on Energy in Human Nutrition.
- 1380 Cao XY, Jiang XM, Dou ZH, Rakeman MA, Zhang ML, O'Donnell K, Ma T, Amette K, DeLong N  
1381 and DeLong GR, 1994. Timing of vulnerability of the brain to iodine deficiency in endemic  
1382 cretinism. *New England Journal of Medicine*, 331, 1739-1744.
- 1383 Capdevila Bert R, Marsal Mora JR, Pujol Salud J and Anguera Farran R, 2010. [Prevalence study of  
1384 iodine deficiency in a 6-year-old school population]. *An Pediatr (Barc)*, 72, 331-338.
- 1385 Cardoso BA and Rosenthal D, 1987. Thyroxine (T4) and triiodothyronine (T3) metabolism in normal  
1386 subjects from Rio de Janeiro, Brazil. *Brazilian Journal of Medical and Biological Research*, 20,  
1387 419-423.
- 1388 Castetbon K, Vernay M, Malon A, Salanave B, Deschamps V, Roudier C, Oleko A, Szego E and  
1389 Hercberg S, 2009. Dietary intake, physical activity and nutritional status in adults: the French  
1390 nutrition and health survey (ENNS, 2006-2007). *British Journal of Nutrition*, 102, 733-743.
- 1391 Chanoine JP, Toppet V, Lagasse R, Spehl M and Delange F, 1991. Determination of thyroid volume  
1392 by ultrasound from the neonatal period to late adolescence. *European Journal of Pediatrics*, 150,  
1393 395-399.
- 1394 Chen ZP and Hetzel BS, 2010. Cretinism revisited. *Best Practice and Research. Clinical*  
1395 *Endocrinology and Metabolism*, 24, 39-50.
- 1396 Cheng SY, Leonard JL and Davis PJ, 2010. Molecular aspects of thyroid hormone actions. *Endocrine*  
1397 *Reviews*, 31, 139-170.
- 1398 Chierici R, Saccomandi D and Vigi V, 1999. Dietary supplements for the lactating mother: influence  
1399 on the trace element content of milk. *Acta Paediatrica. Supplement*, 88, 7-13.
- 1400 Chopra IJ, 1976. An assessment of daily production and significance of thyroidal secretion of 3, 3', 5'-  
1401 triiodothyronine (reverse T3) in man. *Journal of Clinical Investigation*, 58, 32-40.
- 1402 Chueire VB, Romaldini JH and Ward LS, 2007. Subclinical hypothyroidism increases the risk for  
1403 depression in the elderly. *Archives of Gerontology and Geriatrics*, 44, 21-28.
- 1404 Cole VV and Curtis GM, 1935. Human iodine balance - nine figures. *Journal of Nutrition*, 10, 493-  
1405 506.
- 1406 Colzani R, Fang SL, Alex S and Braverman LE, 1998. The effect of nicotine on thyroid function in  
1407 rats. *Metabolism: Clinical and Experimental*, 47, 154-157.
- 1408 Consolazio CF, Matoush LO, Nelson RA, Isaac GJ and Canham JE, 1966. Comparisons of nitrogen,  
1409 calcium and iodine excretion in arm and total body sweat. *American Journal of Clinical Nutrition*,  
1410 18, 443-448.
- 1411 Costa A, De Filippis V, Panizzo M, Giraudi G, Bertino E, Arisio R, Mostert M, Trapani G and Fabris  
1412 C, 1986. Development of thyroid function between VI-IX month of fetal life in humans. *Journal of*  
1413 *Endocrinological Investigation*, 9, 273-280.
- 1414 Costeira MJ, Oliveira P, Ares S, de Escobar GM and Palha JA, 2009. Iodine status of pregnant women  
1415 and their progeny in the Minho Region of Portugal. *Thyroid*, 19, 157-163.



- 1416 Costeira MJ, Oliveira P, Santos NC, Ares S, Saenz-Rico B, de Escobar GM and Palha JA, 2011.  
1417 Psychomotor development of children from an iodine-deficient region. *Journal of Pediatrics*, 159,  
1418 447-453.
- 1419 D-A-CH (Deutsche Gesellschaft für Ernährung, Österreichische Gesellschaft für Ernährung,  
1420 Schweizerische Gesellschaft für Ernährungsforschung, Schweizerische Vereinigung für  
1421 Ernährung), 2013. Referenzwerte für die Nährstoffzufuhr. Neuer Umschau Buchverlag,  
1422 Frankfurt/Main, Germany, 292 pp.
- 1423 Dafnis E and Sabatini S, 1992. The effect of pregnancy on renal function: physiology and  
1424 pathophysiology. *American Journal of the Medical Sciences*, 303, 184-205.
- 1425 Davis PJ, Lin HY, Mousa SA, Luidens MK, Herbergs AA, Wehling M and Davis FB, 2011.  
1426 Overlapping nongenomic and genomic actions of thyroid hormone and steroids. *Steroids*, 76, 829-  
1427 833.
- 1428 DeGroot LJ, 1966. Kinetic analysis of iodine metabolism. *Journal of Clinical Endocrinology and*  
1429 *Metabolism*, 26, 149-173.
- 1430 Delange F, Bourdoux P, Vo Thi LD, Ermans AM and Senterre J, 1984. Negative iodine balance in  
1431 preterm infants. *Annales d'Endocrinologie*, 45, 77.
- 1432 Delange F, Fisher DA, Glinioer D and North Atlantic Treaty Organization Scientific Affairs Division,  
1433 1989. Research in congenital hypothyroidism. Plenum Press, New York, USA, pp. 367.
- 1434 Delange F and Ermans A-M, 1991. Iodine deficiency. In: Werner and Ingbar's *The Thyroid. A*  
1435 *fundamental and clinical text*. Eds Braverman LE and Utiger RD. J.B. Lippincott, Philadelphia,  
1436 USA, 368-390.
- 1437 Delange F, Dunn JT, Glinioer D and North Atlantic Treaty Organization Scientific Affairs Division,  
1438 1993. Iodine deficiency in Europe. A continuing concern. Plenum Press, New York, USA, pp. 492.
- 1439 Delange F, 1994. The disorders induced by iodine deficiency. *Thyroid*, 4, 107-128.
- 1440 Delange F, Benker G, Caron P, Eber O, Ott W, Peter F, Podoba J, Simescu M, Szybinsky Z,  
1441 Vertongen F, Vitti P, Wiersinga W and Zamrazil V, 1997. Thyroid volume and urinary iodine in  
1442 European schoolchildren: standardization of values for assessment of iodine deficiency. *European*  
1443 *Journal of Endocrinology*, 136, 180-187.
- 1444 Delange F, Wolff P, Gnat D, Dramaix M, Pilchen M and Vertongen F, 2001. Iodine deficiency during  
1445 infancy and early childhood in Belgium: does it pose a risk to brain development? *European*  
1446 *Journal of Pediatrics*, 160, 251-254.
- 1447 Delgado E, Diaz-Cadóniga, Tartón T, Bobis ML, Valdés MM and Méndez YA, 2004. Erradicación de  
1448 los trastornos por deficiencia de yodo en Asturias (España): 18 años de yodoprofilaxis con sal.  
1449 *Endocrinología y Nutrición*, 51, 492-496.
- 1450 DH (Department of Health), 1991. Dietary reference values for food energy and nutrients for the  
1451 United Kingdom. Report of the Panel on Dietary Reference Values of the Committee on Medical  
1452 Aspects of Food Policy. HM Stationary Office, London, UK, 212 pp.
- 1453 Di Cosmo C, Fanelli G, Tonacchera M, Ferrarini E, Dimida A, Agretti P, De Marco G, Vitti P,  
1454 Pinchera A, Bevilacqua G, Naccarato AG and Viacava P, 2006. The sodium-iodide symporter  
1455 expression in placental tissue at different gestational age: an immunohistochemical study. *Clinical*  
1456 *Endocrinology*, 65, 544-548.
- 1457 Doerge DR and Sheehan DM, 2002. Goitrogenic and estrogenic activity of soy isoflavones.  
1458 *Environmental Health Perspectives*, 110 Suppl 3, 349-353.
- 1459 Dohan O and Carrasco N, 2003. Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and  
1460 beyond. *Molecular and Cellular Endocrinology*, 213, 59-70.
- 1461 Dorea JG, 2002. Iodine nutrition and breast feeding. *Journal of Trace Elements in Medicine and*  
1462 *Biology*, 16, 207-220.

- 1463 Drees (Direction des études de l'évaluation et des statistiques), 2011. L'état de santé de la population  
1464 en France. Suivi des objectifs annexés à la loi de santé publique. Rapport 2011. 340 pp.
- 1465 Dunn JT, Semigran MJ and Delange F, 1998. The prevention and management of iodine-induced  
1466 hyperthyroidism and its cardiac features. *Thyroid*, 8, 101-106.
- 1467 Dworkin HJ, Jacquez JA and Beierwaltes WH, 1966. Relationship of iodine ingestion to iodine  
1468 excretion in pregnancy. *Journal of Clinical Endocrinology and Metabolism*, 26, 1329-1342.
- 1469 EFSA ANS Panel (EFSA Panel on Food Additives and Nutrient Sources added to Food), 2013.  
1470 Statement on the safety of iodized ethyl esters of poppy seed oil as a source of iodine added for  
1471 nutritional purposes to foodstuffs. *EFSA Journal*, 11(3):3120, 10 pp.
- 1472 EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain), 2008. Opinion of the  
1473 Scientific Panel on Contaminants in the Food Chain on a request from the European Commission  
1474 on glucosinolates as undesirable substances in animal feed. *EFSA Journal* 590, 1-76.
- 1475 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2009. Scientific  
1476 Opinion on the appropriate age for introduction of complementary feeding of infants. *EFSA*  
1477 *Journal*, 7(12): 1423, 38 pp.
- 1478 EFSA NDA Panel (EFSA Panel on Dietetic Products Nutrition and Allergies), 2010. Scientific  
1479 Opinion on Dietary Reference Values for water. *EFSA Journal*, 8(3):1459, 48 pp.
- 1480 Eltom A, Eltom M, Elnagar B, Elbagir M and Gebre-Medhin M, 2000. Changes in iodine metabolism  
1481 during late pregnancy and lactation: a longitudinal study among Sudanese women. *European*  
1482 *Journal of Clinical Nutrition*, 54, 429-433.
- 1483 Erdogan G, Sav H and Erdogan MF, 2000. Iodine status and thyroid volumes of school age children  
1484 from Northern Cyprus. *Journal of Endocrinological Investigation*, 23, 74-77.
- 1485 Etling N, 1977. Concentration of thyroglobulin, iodine contents of thyroglobulin and of  
1486 iodoaminoacids in human neonates thyroid glands. *Acta Paediatrica Scandinavica*, 66, 97-102.
- 1487 Etling N, Padovani E, Gehin-Fouque F and Tato L, 1983. Iodine and thyroid hormone levels in serum  
1488 and urine of full term newborn infants. *Helvetica Paediatrica Acta*, 38, 117-122.
- 1489 Etling N and Gehin-Fouque F, 1984. Iodinated compounds and thyroxine binding to albumin in human  
1490 breast milk. *Pediatric Research*, 18, 901-903.
- 1491 Etling N, Padovani E, Fouque F and Tato L, 1986. First-month variations in total iodine content of  
1492 human breast milks. *Early Human Development*, 13, 81-85.
- 1493 Evans TC, Kretzschmar RM, Hodges RE and Song CW, 1967. Radioiodine uptake studies of the  
1494 human fetal thyroid. *Journal of Nuclear Medicine*, 8, 157-165.
- 1495 Faber J, Poulsen S, Iversen P and Kirkegaard C, 1988. Thyroid hormone turnover in patients with  
1496 small cell carcinoma of the lung. *Acta Endocrinologica*, 118, 460-464.
- 1497 FAO/WHO (Food and Agriculture Organization of the United Nations/World Health Organization),  
1498 2011. Evaluation of certain contaminants in food. 72nd report of the Joint FAO/WHO Expert  
1499 Committee on Food Additives. WHO Technical Report Series 959, 115 pp.
- 1500 FAO/WHO/UNU (Food and Agriculture Organization of the United Nations/World Health  
1501 Organization/United Nations University), 2004. Human energy requirements. Report of a Joint  
1502 FAO/WHO/UNU Expert Consultation: Rome, 17–24 October 2001. FAO food and nutrition  
1503 technical report series, 103 pp.
- 1504 Farkas I, Sajgo K and 1997. Goiter frequency among boys of I-IV class of primary schools: reports to  
1505 the Ministry of Health 94/95, 95/96, 96, 97. *Public Health of Budapest*; 1 15-9.
- 1506 Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP and Oppenheimer JH, 1987.  
1507 Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of

- 1508       hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. *New England Journal of*  
1509       *Medicine*, 316, 764-770.
- 1510       Fisher DA and Oddie TH, 1969a. Thyroidal radioiodine clearance and thyroid iodine accumulation:  
1511       contrast between random daily variation and population data. *Journal of Clinical Endocrinology*  
1512       *and Metabolism*, 29, 111-115.
- 1513       Fisher DA and Oddie TH, 1969b. Thyroid iodine content and turnover in euthyroid subjects: validity  
1514       of estimation of thyroid iodine accumulation from short-term clearance studies. *Journal of Clinical*  
1515       *Endocrinology and Metabolism*, 29, 721-727.
- 1516       Fister P, Gaberscek S, Zaletel K, Krhin B, Hojker S and Gersak K, 2011. Thyroid function in the third  
1517       trimester of pregnancy and after delivery in an area of adequate iodine intake. *International Journal*  
1518       *of Gynaecology and Obstetrics*, 112, 52-55.
- 1519       Follis RH, Jr., Vanprapa K and Damrongsakdi D, 1962. Studies on iodine nutrition in Thailand.  
1520       *Journal of Nutrition*, 76, 159-173.
- 1521       Forth W, Henschler D and Rummel W, 1987. *Allgemeine und spezielle Pharmakologie und*  
1522       *Toxikologie*. Wissenschaftsverlag, Mannheim, 436-443.
- 1523       Gaitan E, 1990. Goitrogens in food and water. *Annual Review of Nutrition*, 10, 21-39.
- 1524       Garcia-Fuentes E, Gallo M, Garcia L, Prieto S, Alcaide-Torres J, Santiago P, Velasco I and Soriguer  
1525       F, 2008. Amniotic fluid iodine concentrations do not vary in pregnant women with varying iodine  
1526       intake. *British Journal of Nutrition*, 99, 1178-1181.
- 1527       Gardner DF, Centor RM and Utiger RD, 1988. Effects of low dose oral iodide supplementation on  
1528       thyroid function in normal men. *Clinical Endocrinology*, 28, 283-288.
- 1529       Gavin L, Castle J, McMahon F, Martin P, Hammond M and Cavalieri RR, 1977. Extrathyroidal  
1530       conversion of thyroxine to 3,3',5'-triiodothyronine (reverse-T3) and to 3,5,3'-triiodothyronine (T3)  
1531       in humans. *Journal of Clinical Endocrinology and Metabolism*, 44, 733-742.
- 1532       Glinioer D, Lemone M, Bourdoux P, De Nayer P, DeLange F, Kinthaert J and LeJeune B, 1992. Partial  
1533       reversibility during late postpartum of thyroid abnormalities associated with pregnancy. *Journal of*  
1534       *Clinical Endocrinology and Metabolism*, 74, 453-457.
- 1535       Glinioer D, De Nayer P, Delange F, Lemone M, Toppet V, Spehl M, Grun JP, Kinthaert J and Lejeune  
1536       B, 1995. A randomized trial for the treatment of mild iodine deficiency during pregnancy: maternal  
1537       and neonatal effects. *Journal of Clinical Endocrinology and Metabolism*, 80, 258-269.
- 1538       Glinioer D, 1997. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation  
1539       from physiology to pathology. *Endocrine Reviews*, 18, 404-433.
- 1540       Glinioer D, 1998. Iodine supplementation during pregnancy: importance and biochemical assessment.  
1541       *Experimental and Clinical Endocrinology and Diabetes*, 106 Suppl 3, S21.
- 1542       Glinioer D, 2001. Pregnancy and iodine. *Thyroid*, 11, 471-481.
- 1543       Glinioer D, 2007. The importance of iodine nutrition during pregnancy. *Public Health Nutrition*, 10,  
1544       1542-1546.
- 1545       Goellner MH, Ziegler EE and Fomon SJ, 1981. Urination during the first three years of life. *Nephron*,  
1546       28, 174-178.
- 1547       Gokmen IG and Dagli G, 1995. Determination of iodine concentration in human milk, cows' milk and  
1548       infant formula and estimation of daily iodine intake of infants. *Analyst*, 120, 2005-2008.
- 1549       Greenberg AH, Czernichow P, Reba RC, Tyson J and Blizzard RM, 1970. Observations on the  
1550       maturation of thyroid function in early fetal life. *Journal of Clinical Investigation*, 49, 1790-1803.
- 1551       Gunnarsdottir I and Dahl L, 2012. Iodine intake in human nutrition: a systematic literature review.  
1552       *Food Nutr Res*, 56.

- 1553 Gushurst CA, Mueller JA, Green JA and Sedor F, 1984. Breast milk iodide: Reassessment in the  
1554 1980s. *Pediatrics*, 73, 354 -357
- 1555 Gutekunst R, Becker W, Hehrmann R, Olbricht T and Pfannenstiel P, 1988. [Ultrasonic diagnosis of  
1556 the thyroid gland]. *Deutsche Medizinische Wochenschrift*, 113, 1109-1112.
- 1557 Harden RM and Alexander WD, 1963. Quantitative aspects of iodide excretion in human thermal  
1558 sweat. *Clinical Science*, 25, 79-87.
- 1559 Harrison MT, Harden RM, Alexander WD and Wayne E, 1965. Iodine balance studies in patients with  
1560 normal and abnormal thyroid function. *Journal of Clinical Endocrinology and Metabolism*, 25,  
1561 1077-1084.
- 1562 Harrison MT, 1968. Iodine balance in man. *Postgraduate Medical Journal*, 44, 69-71.
- 1563 Hays MT, 1991. Localization of human thyroxine absorption. *Thyroid*, 1, 241-248.
- 1564 Health Council of the Netherlands, 2008. Towards maintaining an optimum iodine intake. publication  
1565 no. 2008/14E, The Hague, Netherlands.
- 1566 Heidemann PH, Stubbe P and Thal H, 1986. Influence of iodine prophylaxis on thyroid function and  
1567 iodine excretion in newborn infants and their mothers: comparison between Sweden and Germany.  
1568 *Acta Endocrinologica*, 3, 48-48.
- 1569 Henrichs J, Bongers-Schokking JJ, Schenk JJ, Ghassabian A, Schmidt HG, Visser TJ, Hooijkaas H, de  
1570 Muinck Keizer-Schrama SM, Hofman A, Jaddoe VV, Visser W, Steegers EA, Verhulst FC, de  
1571 Rijke YB and Tiemeier H, 2010. Maternal thyroid function during early pregnancy and cognitive  
1572 functioning in early childhood: the generation R study. *Journal of Clinical Endocrinology and  
1573 Metabolism*, 95, 4227-4234.
- 1574 Hooper PL, Turner JR, Conway MJ and Plymate SR, 1980. Thyroid uptake of <sup>123</sup>I in a normal  
1575 population. *Archives of Internal Medicine*, 140, 757-758.
- 1576 Hynes KL, Otahal P, Hay I and Burgess JR, 2013. Mild Iodine Deficiency During Pregnancy Is  
1577 Associated With Reduced Educational Outcomes in the Offspring: 9-Year Follow-up of the  
1578 Gestational Iodine Cohort. *Journal of Clinical Endocrinology and Metabolism*, 98, 1954-1962.
- 1579 IDD Newsletter, 2000. IDD in the Baltics. *IDD Newsletter*; 16.
- 1580 Ingenbleek Y and Malvaux P, 1974. Iodine balance studies in protein-calorie malnutrition. *Archives of  
1581 Disease in Childhood*, 49, 305-309.
- 1582 IOM (Institute of Medicine), 2001. Dietary Reference Intakes for vitamin A, vitamin K, arsenic,  
1583 boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and  
1584 zinc. National Academies Press, Washington DC, USA, 797 pp.
- 1585 Jahreis G, Hausmann W, Kiessling G, Franke K and Leiterer M, 2001. Bioavailability of iodine from  
1586 normal diets rich in dairy products--results of balance studies in women. *Experimental and Clinical  
1587 Endocrinology and Diabetes*, 109, 163-167.
- 1588 Johner SA, Shi L and Remer T, 2010. Higher urine volume results in additional renal iodine loss.  
1589 *Thyroid*, 20, 1391-1397.
- 1590 Jonckheer MH, 1987. Clinical usefulness of thyroid imaging by means of X-ray fluorescence.  
1591 *Hormone Research*, 26, 42-47.
- 1592 Kahaly G, Dienes HP, Beyer J and Hommel G, 1997. Randomized, double blind, placebo-controlled  
1593 trial of low dose iodide in endemic goiter. *Journal of Clinical Endocrinology and Metabolism*, 82,  
1594 4049-4053.
- 1595 Kahaly GJ, Dienes HP, Beyer J and Hommel G, 1998. Iodide induces thyroid autoimmunity in  
1596 patients with endemic goitre: a randomised, double-blind, placebo-controlled trial. *European  
1597 Journal of Endocrinology*, 139, 290-297.

- 1598 Kahaly GJ and Dillmann WH, 2005. Thyroid hormone action in the heart. *Endocrine Reviews*, 26,  
1599 704-728.
- 1600 Kaplan MM, 1992. Monitoring thyroxine treatment during pregnancy. *Thyroid*, 2, 147-152.
- 1601 Karagiannis G, Ashoor G, Maiz N, Jawdat F and Nicolaides KH, 2011. Maternal thyroid function at  
1602 eleven to thirteen weeks of gestation and subsequent delivery of small for gestational age neonates.  
1603 *Thyroid*, 21, 1127-1131.
- 1604 Kirk AB, Dyke JV, Martin CF and Dasgupta PK, 2007. Temporal patterns in perchlorate, thiocyanate,  
1605 and iodide excretion in human milk. *Environmental Health Perspectives*, 115, 182-186.
- 1606 Kirkegaard C, Korner A and Faber J, 1990. Increased production of thyroxine and inappropriately  
1607 elevated serum thyrotropin in levels in endogenous depression. *Biological Psychiatry*, 27, 472-476.
- 1608 Knudsen N, Bulow I, Laurberg P, Ovesen L, Perrild H and Jorgensen T, 2002. Association of tobacco  
1609 smoking with goiter in a low-iodine-intake area. *Archives of Internal Medicine*, 162, 439-443.
- 1610 Köhrle J and Gärtner R, 2009. Selenium and thyroid. *Best Practice and Research. Clinical*  
1611 *Endocrinology and Metabolism*, 23, 815-827.
- 1612 Kostalova L, 2003. Urinary iodine assessment in children in Slovakia. Bratislava: Children's  
1613 University Hospital.
- 1614 Kotnik P, Sirca Campa A, Zupancic M, Stimec M, Smole K, Mis NF, Battelino T and Krzisnik C,  
1615 2006. Goiter prevalence and urinary iodine concentration in Slovenian adolescents. *Thyroid*, 16,  
1616 769-773.
- 1617 Kovatcheva R, Angelova K, Timcheva T and Vukov M, 2011. Iodine nutrition in Bulgaria. ICCIDD  
1618 West-Central Europe regional meeting. Satellite to 35th annual ETA meeting. September, 2011,  
1619 Krakow, Poland.
- 1620 Krassas GE, Poppe K and Glinioer D, 2010. Thyroid function and human reproductive health.  
1621 *Endocrine Reviews*, 31, 702-755.
- 1622 Kurtoglu S, Akcakus M, Kocaoglu C, Gunes T, Budak N, Atabek ME, Karakucuk I and Delange F,  
1623 2004. Iodine status remains critical in mother and infant in Central Anatolia (Kayseri) of Turkey.  
1624 *European Journal of Nutrition*, 43, 297-303.
- 1625 Kusic Z, Jukic T, Rogan SA, Juresa V, Dabelic N, Stanicic J, Boric M, Lukinac L, Mihaljevic I, Punda  
1626 A, Smokvina A, Topalovic Z and Katalenic M, 2012. Current status of iodine intake in Croatia--the  
1627 results of 2009 survey. *Collegium Antropologicum*, 36, 123-128.
- 1628 Lahesmaa P and Vilkki P, 1960. The iodine content of human milk in Finland. *Acta Paediatrica*, 49,  
1629 371-376.
- 1630 Lamberg BA, 1986. Endemic goitre in Finland and changes during 30 years of iodine prophylaxis.  
1631 *Endocrinologia Experimentalis*, 20, 35-47.
- 1632 Laurberg P, Pedersen KM, Hreidarsson A, Sigfusson N, Iversen E and Knudsen PR, 1998. Iodine  
1633 intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid  
1634 abnormalities in the elderly in Iceland and in Jutland, Denmark. *Journal of Clinical Endocrinology*  
1635 *and Metabolism*, 83, 765-769.
- 1636 Laurberg P, Nohr SB, Pedersen KM and Fuglsang E, 2004. Iodine nutrition in breast-fed infants is  
1637 impaired by maternal smoking. *Journal of Clinical Endocrinology and Metabolism*, 89, 181-187.
- 1638 Laurberg P, Andersen S, Bjarnadottir RI, Carle A, Hreidarsson A, Knudsen N, Ovesen L, Pedersen I  
1639 and Rasmussen L, 2007. Evaluating iodine deficiency in pregnant women and young infants-  
1640 complex physiology with a risk of misinterpretation. *Public Health Nutrition*, 10, 1547-1552;  
1641 discussion 1553.



- 1642 Laurberg P, Cerqueira C, Ovesen L, Rasmussen LB, Perrild H, Andersen S, Pedersen IB and Carle A,  
1643 2010. Iodine intake as a determinant of thyroid disorders in populations. Best Practice and  
1644 Research. Clinical Endocrinology and Metabolism, 24, 13-27.
- 1645 Liberman CS, Pino SC, Fang SL, Braverman LE and Emerson CH, 1998. Circulating iodide  
1646 concentrations during and after pregnancy. Journal of Clinical Endocrinology and Metabolism, 83,  
1647 3545-3549.
- 1648 Limbert E, Prazeres S, Sao Pedro M, Madureira D, Miranda A, Ribeiro M, Carrilho F, Jacome de  
1649 Castro J, Lopes MS, Cardoso J, Carvalho A, Oliveira MJ, Reguengo H, Borges F and Grupo de  
1650 Estudos da Tiroide da Sociedade Portuguesa de Endocrinologia Diabetes e M, 2012. [Iodine intake  
1651 in Portuguese school children]. Acta Medica Portuguesa, 25, 29-36.
- 1652 Lind P, Kumnig G, Heinisch M, Igerc I, Mikosch P, Gallowitsch HJ, Kresnik E, Gomez I, Unterweger  
1653 O and Aigner H, 2002. Iodine supplementation in Austria: methods and results. Thyroid, 12, 903-  
1654 907.
- 1655 Madueno Caro AJ, Cabezas Saura PB, Diaz Orta J, Benitez Rodriguez E, Ruiz Galdon M and Gomez  
1656 A, 2001. [Prevalence of goitre and iodine deficiency in a school population from a traditionally  
1657 endemic health area]. Atencion Primaria, 27, 258-262.
- 1658 Maia AL, Goemann IM, Meyer EL and Wajner SM, 2011. Deiodinases: the balance of thyroid  
1659 hormone: type 1 iodothyronine deiodinase in human physiology and disease. Journal of  
1660 Endocrinology, 209, 283-297.
- 1661 Malamos B, Koutras DA, Marketos SG, Rigopoulos GA, Yataganas XA, Binopoulos D, Sfontouris J,  
1662 Pharmakiotis AD, Vought RL and London WT, 1967. Endemic goiter in Greece: an iodine balance  
1663 study in the field. Journal of Clinical Endocrinology and Metabolism, 27, 1372-1380.
- 1664 Malvaux P, Beckers C and De Visscher M, 1969. Iodine balance studies in nongoitrous children and in  
1665 adolescents on low iodine intake. Journal of Clinical Endocrinology and Metabolism, 29, 79-84.
- 1666 Mandel SJ, Larsen PR, Seely EW and Brent GA, 1990. Increased need for thyroxine during pregnancy  
1667 in women with primary hypothyroidism. New England Journal of Medicine, 323, 91-96.
- 1668 Mao IF, Ko YC and Chen ML, 1990. The stability of iodine in human sweat. Japanese Journal of  
1669 Physiology, 40, 693-700.
- 1670 Mao IF, Chen ML and Ko YC, 2001. Electrolyte loss in sweat and iodine deficiency in a hot  
1671 environment. Archives of Environmental Health, 56, 271-277.
- 1672 Marino C, Martinelli M, Monacelli G, Stracci F, Stalteri D, Mastrandrea V, Puxeddu E and  
1673 Santeusano F, 2006. Evaluation of goiter using ultrasound criteria: a survey in a middle  
1674 schoolchildren population of a mountain area in Central Italy. Journal of Endocrinological  
1675 Investigation, 29, 869-875.
- 1676 Mattsson S and Lindstrom S, 1995. Diuresis and voiding pattern in healthy schoolchildren. British  
1677 Journal of Urology, 76, 783-789.
- 1678 Mazzarella C, Terracciano D, Di Carlo A, Macchia PE, Consiglio E, Macchia V and Mariano A, 2009.  
1679 Iodine status assessment in Campania (Italy) as determined by urinary iodine excretion. Nutrition,  
1680 25, 926-929.
- 1681 McConahey WH, Keating FR, Jr., and Power MH, 1951. An estimation of the renal and extrarenal  
1682 clearance of radioiodide in man. Journal of Clinical Investigation, 30, 778-780.
- 1683 Mendez W, Jr. and Eftim SE, 2012. Biomarkers of perchlorate exposure are correlated with circulating  
1684 thyroid hormone levels in the 2007-2008 NHANES. Environmental Research, 118, 137-144.
- 1685 Mertz W, 1987. Use and misuse of balance studies. Journal of Nutrition, 117, 1811-1813.
- 1686 Michalke B, Schramel P and Witte H, 2000. Iodine speciation in human serum by reversed-phase  
1687 liquid chromatography-ICP-mass spectrometry. Biological Trace Element Research, 78, 81-91.

- 1688 Milakovic M, Berg G, Eggertsen R, Nystrom E, Olsson A, Larsson A and Hansson M, 2006.  
1689 Determination of intrathyroidal iodine by X-ray fluorescence analysis in 60- to 65-year olds living  
1690 in an iodine-sufficient area. *Journal of Internal Medicine*, 260, 69-75.
- 1691 Ministère de la Santé and Direction de la Santé, 2002. Etude sur l'évaluation de la iodurie effectuée en  
1692 milieu scolaire Luxembourg. Ministry of Health of Luxembourg.
- 1693 Montenegro-Bethancourt G, Johnner SA and Remer T, 2013. Contribution of fruit and vegetable intake  
1694 to hydration status in schoolchildren. *American Journal of Clinical Nutrition*, 98, 1103-1112.
- 1695 Moon S and Kim J, 1999. Iodine content of human milk and dietary iodine intake of Korean lactating  
1696 mothers. *International Journal of Food Sciences and Nutrition*, 50, 165-171.
- 1697 Morreale de Escobar G, Obregon MJ and Escobar del Rey F, 2004. Role of thyroid hormone during  
1698 early brain development. *European Journal of Endocrinology*, 151 Suppl 3, U25-37.
- 1699 Mouloupoulos DS, Koutras DA, Mantzos J, Souvatzoglou A, Piperlingos GD, Karaikos KS,  
1700 Makriyannis D, Sfontouris J and Mouloupoulos SD, 1988. The relation of serum T4 and TSH with  
1701 the urinary iodine excretion. *Journal of Endocrinological Investigation*, 11, 437-439.
- 1702 Nath SK, Moinier B, Thuillier F, Rongier M and Desjeux JF, 1992. Urinary excretion of iodide and  
1703 fluoride from supplemented food grade salt. *International Journal for Vitamin and Nutrition*  
1704 *Research*, 62, 66-72.
- 1705 Nicola JP, Basquin C, Portulano C, Reyna-Neyra A, Paroder M and Carrasco N, 2009. The Na<sup>+</sup>/I-  
1706 symporter mediates active iodide uptake in the intestine. *American Journal of Physiology. Cell*  
1707 *Physiology*, 296, C654-662.
- 1708 Nicoloff JT, Low JC, Dussault JH and Fisher DA, 1972. Simultaneous measurement of thyroxine and  
1709 triiodothyronine peripheral turnover kinetics in man. *Journal of Clinical Investigation*, 51, 473-483.
- 1710 NNR (Nordic Nutrition Recommendations), 2004. Integrating nutrition and physical activity. Nordic  
1711 Council of Ministers, Copenhagen, Denmark, 436 pp.
- 1712 Nohr SB, Laurberg P, Borlum KG, Pedersen KM, Johannesen PL, Damm P, Fuglsang E and Johansen  
1713 A, 1994. Iodine status in neonates in Denmark: regional variations and dependency on maternal  
1714 iodine supplementation. *Acta Paediatrica*, 83, 578-582.
- 1715 Nordic Council of Ministers, 2002. The influence of chemicals in the food and the environment on the  
1716 thyroid gland function. *TemaNord 2002:520*, 87 pp.
- 1717 Nordic Council of Ministers, 2013. Nordic Nutrition Recommendations 2012. Part 1. Summary,  
1718 principles and use. 85 pp.
- 1719 Patel J, Landers K, Li H, Mortimer RH and Richard K, 2011. Delivery of maternal thyroid hormones  
1720 to the fetus. *Trends in Endocrinology and Metabolism*, 22, 164-170.
- 1721 Paul T, Meyers B, Witorsch RJ, Pino S, Chipkin S, Ingbar SH and Braverman LE, 1988. The effect of  
1722 small increases in dietary iodine on thyroid function in euthyroid subjects. *Metabolism: Clinical*  
1723 *and Experimental*, 37, 121-124.
- 1724 Pedersen KM, Laurberg P, Iversen E, Knudsen PR, Gregersen HE, Rasmussen OS, Larsen KR,  
1725 Eriksen GM and Johannesen PL, 1993. Amelioration of some pregnancy-associated variations in  
1726 thyroid function by iodine supplementation. *Journal of Clinical Endocrinology and Metabolism*,  
1727 77, 1078-1083.
- 1728 Pettigrew-Porter A, Skeaff S, Gray A, Thomson C and Croxson M, 2011. Are pregnant women in  
1729 New Zealand iodine deficient? A cross-sectional survey. *Australian and New Zealand Journal of*  
1730 *Obstetrics and Gynaecology*, 51, 464-467.
- 1731 Pharoah PO, Butfield IH and Hetzel BS, 1971. Neurological damage to the fetus resulting from severe  
1732 iodine deficiency during pregnancy. *Lancet*, 1, 308-310.

- 1733 Phillips DI, Nelson M, Barker DJ, Morris JA and Wood TJ, 1988. Iodine in milk and the incidence of  
1734 thyrotoxicosis in England. *Clinical Endocrinology*, 28, 61-66.
- 1735 Phillips DI, 1997. Iodine, milk, and the elimination of endemic goitre in Britain: the story of an  
1736 accidental public health triumph. *Journal of Epidemiology and Community Health*, 51, 391-393.
- 1737 Queenan JT, Thompson W, Whitfield CR and Shah SI, 1972. Amniotic fluid volumes in normal  
1738 pregnancies. *American Journal of Obstetrics and Gynecology*, 114, 34-38.
- 1739 Rapa A, Chiorboli E, Sartorio A and Bona G, 1999a. Puberty and urinary iodine excretion. *Journal of*  
1740 *Pediatric Endocrinology and Metabolism*, 12, 583-584.
- 1741 Rapa A, Marinello D, Chiorboli E, Sacco F and Bona G, 1999b. Iodine deficiency in Italy. Italian  
1742 Study Group on Urinary Iodine of SIEDP. *Lancet*, 354, 596-597.
- 1743 Rasmussen LB, Carle A, Jorgensen T, Knudsen N, Laurberg P, Pedersen IB, Perrild H, Vejbjerg P and  
1744 Ovesen L, 2008. Iodine intake before and after mandatory iodization in Denmark: results from the  
1745 Danish Investigation of Iodine Intake and Thyroid Diseases (DanThyr) study. *British Journal of*  
1746 *Nutrition*, 100, 166-173.
- 1747 Rayburn WF, Robinson A, Braverman LE, He XM, Pino S, Gargas ML and Kinzell JH, 2008. Iodide  
1748 concentrations in matched maternal serum, cord serum, and amniotic fluid from preterm and term  
1749 human pregnancies. *Reproductive Toxicology*, 25, 129-132.
- 1750 Rebagliato M, Murcia M, Espada M, Alvarez-Pedrerol M, Bolumar F, Vioque J, Basterrechea M,  
1751 Blarduni E, Ramon R, Guxens M, Foradada CM, Ballester F, Ibarluzea J and Sunyer J, 2010.  
1752 Iodine intake and maternal thyroid function during pregnancy. *Epidemiology*, 21, 62-69.
- 1753 Rebagliato M, Vioque J and Arrizabalaga JJ, 2013. Iodine supplements during and after pregnancy.  
1754 *JAMA*, 309, 1345-1346.
- 1755 Reinwein D, Durrer HA and Meinhold H, 1981. Iodine, thyroxine (T<sub>4</sub>), triiodothyronine (T<sub>3</sub>), 3,3',5'-  
1756 triiodothyronine (rT<sub>3</sub>), 3,3'-diiodothyronine (T<sub>2</sub>) in normal human thyroids. Effect of excessive  
1757 iodine exposure. *Hormone and Metabolic Research*, 13, 456-459.
- 1758 Ristić-Medić D, Piskackova Z, Hooper L, Ruprich J, Casgrain A, Ashton K, Pavlovic M and Glibetic  
1759 M, 2009. Methods of assessment of iodine status in humans: a systematic review. *American*  
1760 *Journal of Clinical Nutrition*, 89, 2052S-2069S.
- 1761 Ristić-Medić D, Novaković R, Glibetić M and Gurinović M, 2013. EURRECA - Estimating iodine  
1762 requirements for deriving dietary reference values. *Critical Reviews in Food Science and Nutrition*,  
1763 53, 1051-1063.
- 1764 Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, Asvold BO, Iervasi G,  
1765 Imaizumi M, Collet TH, Bremner A, Maisonneuve P, Sgarbi JA, Khaw KT, Vanderpump MP,  
1766 Newman AB, Cornuz J, Franklyn JA, Westendorp RG, Vittinghoff E, Gussekloo J and Thyroid  
1767 Studies C, 2010. Subclinical hypothyroidism and the risk of coronary heart disease and mortality.  
1768 *JAMA*, 304, 1365-1374.
- 1769 Rokita SE, Adler JM, McTamney PM and Watson JA, Jr., 2010. Efficient use and recycling of the  
1770 micronutrient iodide in mammals. *Biochimie*, 92, 1227-1235.
- 1771 Romano R, Jannini EA, Pepe M, Grimaldi A, Olivieri M, Spennati P, Cappa F and D'Armiento M,  
1772 1991. The effects of iodoprophylaxis on thyroid size during pregnancy. *American Journal of*  
1773 *Obstetrics and Gynecology*, 164, 482-485.
- 1774 Roti E, Fang SL, Emerson CH and Braverman LE, 1981. Placental inner ring iodothyronine  
1775 deiodination: a mechanism for decreased passage of T<sub>4</sub> and T<sub>3</sub> from mother to fetus. *Transactions*  
1776 *of the Association of American Physicians*, 94, 183-189.
- 1777 Roti E and Vagenakis G, 2000. Effect of excess iodide: clinical aspects. In: *The thyroid. A*  
1778 *fundamental and clinical text*. Eds Braverman LE and Utiger RD. Lippincott Williams & Wilkins,  
1779 Philadelphia, USA, 316-329.

- 1780 Saggiorato E, Mussa A, Sacerdote C, Rossetto R, Arecco F, Origlia C, Germano L, Deandreis D,  
1781 Orlandi F and Piemonte Goiter Study C, 2004. Thyroid volume and urinary iodine excretion in the  
1782 schoolchild population of a Northwestern Italian sub-Alp metropolitan area. *Journal of*  
1783 *Endocrinological Investigation*, 27, 516-522.
- 1784 Saggiorato E, Arecco F, Mussa A, Sacerdote C, Rossetto R, Origlia C, Germano L, Deandreis D,  
1785 Orlandi F and Piedmont Goiter Study C, 2006. Goiter prevalence and urinary iodine status in urban  
1786 and rural/mountain areas of Piedmont region. *Journal of Endocrinological Investigation*, 29, 67-73.
- 1787 Santiago-Fernandez P, Torres-Barahona R, Muela-Martinez JA, Rojo-Martinez G, Garcia-Fuentes E,  
1788 Garriga MJ, Leon AG and Soriguer F, 2004. Intelligence quotient and iodine intake: a cross-  
1789 sectional study in children. *Journal of Clinical Endocrinology and Metabolism*, 89, 3851-3857.
- 1790 Santiago MI, Fernández S, Ríos M, Fluiters E, Hervada X and Iglesias YT, 2005. Excreción urinaria  
1791 de yodo en escolares de Galicia. *Endocrinología y Nutrición*, 52, 498-505.
- 1792 Savin S, Cvejic D, Nedic O and Radosavljevic R, 2003. Thyroid hormone synthesis and storage in the  
1793 thyroid gland of human neonates. *Journal of Pediatric Endocrinology and Metabolism*, 16, 521-  
1794 528.
- 1795 SCF (Scientific Committee for Food), 1993. Report on nutrient and energy intakes for the European  
1796 Community, 31st Series. Food - Science and Technique, European Commission, Luxembourg, 255  
1797 pp.
- 1798 SCF (Scientific Committee on Food), 2002. Opinion of the Scientific Committee on Food on the  
1799 Tolerable Upper Intake Level of Iodine. 15 pp.
- 1800 SCF (Scientific Committee on Food), 2003. Report of the Scientific Committee on Food on the  
1801 Revision of Essential Requirements of Infant Formulae and Follow-on Formulae. 211 pp.  
1802 [http://ec.europa.eu/food/fs/sc/scf/out199\\_en.pdf](http://ec.europa.eu/food/fs/sc/scf/out199_en.pdf).
- 1803 Selga G, Sauka M and Gerasimov G, 2000. Status of iodine deficiency in Latvia reconsidered: Results  
1804 of a nationwide survey of school children in the year 2000. *IDD Newsletter*;16, 2 pp.
- 1805 Semba RD and Delange F, 2001. Iodine in human milk: perspectives for infant health. *Nutrition*  
1806 *Reviews*, 59, 269-278.
- 1807 Serra-Prat M, Diaz E, Verde Y, Gost J, Serra E and Puig Domingo M, 2003. [Prevalence of iodine  
1808 deficiency and related factors in 4 year-old schoolchildren]. *Medicina Clinica*, 120, 246-249.
- 1809 Shirreffs SM and Maughan RJ, 2005. Water-electrolyte balance. In: *Encyclopedia of Human*  
1810 *Nutrition*. Ed Caballero B AL, Prentice A. Elsevier, Oxford, UK, 100-105.
- 1811 Simonsick EM, Newman AB, Ferrucci L, Satterfield S, Harris TB, Rodondi N, Bauer DC and Health  
1812 ABCS, 2009. Subclinical hypothyroidism and functional mobility in older adults. *Archives of*  
1813 *Internal Medicine*, 169, 2011-2017.
- 1814 Skeaff SA, 2011. Iodine deficiency in pregnancy: the effect on neurodevelopment in the child.  
1815 *Nutrients*, 3, 265-273.
- 1816 Skeaff SA, 2012. Assessing iodine intakes in pregnancy and strategies for improvement. *Journal of*  
1817 *Trace Elements in Medicine and Biology*, 26, 141-144.
- 1818 Smyth P, 2002. *IDD status in Ireland*. Department of Medicine, University College of Dublin.
- 1819 Smyth PP, Hetherington AM, Smith DF, Radcliff M and O'Herlihy C, 1997. Maternal iodine status and  
1820 thyroid volume during pregnancy: correlation with neonatal iodine intake. *Journal of Clinical*  
1821 *Endocrinology and Metabolism*, 82, 2840-2843.
- 1822 Smyth PP and Duntas LH, 2005. Iodine uptake and loss-can frequent strenuous exercise induce iodine  
1823 deficiency? *Hormone and Metabolic Research*, 37, 555-558.



- 1824 Somwaru LL, Rariy CM, Arnold AM and Cappola AR, 2012. The natural history of subclinical  
1825 hypothyroidism in the elderly: the cardiovascular health study. *Journal of Clinical Endocrinology*  
1826 and *Metabolism*, 97, 1962-1969.
- 1827 Soriguer F, Garcia-Fuentes E, Gutierrez-Repiso C, Rojo-Martinez G, Velasco I, Goday A, Bosch-  
1828 Comas A, Bordiu E, Calle A, Carmena R, Casamitjana R, Castano L, Castell C, Catala M, Delgado  
1829 E, Franch J, Gaztambide S, Girbes J, Gomis R, Gutierrez G, Lopez-Alba A, Martinez-Larrad MT,  
1830 Menendez E, Mora-Peces I, Ortega E, Pascual-Manich G, Serrano-Rios M, Valdes S, Vazquez JA  
1831 and Vendrell J, 2012. Iodine intake in the adult population. Di@bet.es study. *Clinical Nutrition*, 31,  
1832 882-888.
- 1833 Spector H, Mitchell HH and Hamilton TS, 1945. The effect of environmental temperature and  
1834 potassium iodide supplementation on the excretion of iodine by normal human subjects. *Journal of*  
1835 *Biological Chemistry*, 161, 137-143.
- 1836 Stanbury JB, 1960. Physiology of endemic goitre. In: *Endemic goitre*. Monograph Series n°44. Ed  
1837 WHO. World Health Organization, Geneva, Switzerland, 261-262.
- 1838 Stanbury JB, Ermans AM, Hetzel BS, Pretell EA and Querido A, 1974. Endemic goitre and cretinism:  
1839 public health significance and prevention. *WHO Chronicle*, 28, 220-228.
- 1840 Stilwell G, Reynolds PJ, Parameswaran V, Blizzard L, Greenaway TM and Burgess JR, 2008. The  
1841 influence of gestational stage on urinary iodine excretion in pregnancy. *Journal of Clinical*  
1842 *Endocrinology and Metabolism*, 93, 1737-1742.
- 1843 Stockton LK and Thomas WC, 1978. Absence of neonatal goitre during maternal use of iodinated  
1844 water. *Clinical Research*, 26, 536A.
- 1845 Subudhi AW, Askew EW and Luetkemeier MJ, 2005. Dehydration. In: *Encyclopedia of Human*  
1846 *Nutrition*. Ed Caballero B AL, Prentice A. Elsevier, Oxford, UK, 518-525.
- 1847 Suzuki M and Tamura T, 1985. Iodine intake of Japanese male university students: urinary iodine  
1848 excretion of sedentary and physically active students and sweat iodine excretion during exercise.  
1849 *Journal of Nutritional Science and Vitaminology*, 31, 409-415.
- 1850 Szybinski Z, 2011. Iodine nutrition in Poland. ICCIDD West-Central Europe regional meeting.  
1851 Satellite to 35th annual ETA meeting. September, 2011, Krakow, Poland.
- 1852 Teng W, Shan Z, Teng X, Guan H, Li Y, Teng D, Jin Y, Yu X, Fan C, Chong W, Yang F, Dai H, Yu  
1853 Y, Li J, Chen Y, Zhao D, Shi X, Hu F, Mao J, Gu X, Yang R, Tong Y, Wang W, Gao T and Li C,  
1854 2006. Effect of iodine intake on thyroid diseases in China. *New England Journal of Medicine*, 354,  
1855 2783-2793.
- 1856 Thamm M, Ellert U, Thierfelder W, Liesenkotter KP and Volzke H, 2007. [Iodine intake in Germany.  
1857 Results of iodine monitoring in the German Health Interview and Examination Survey for Children  
1858 and Adolescents (KiGGS)]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*, 50,  
1859 744-749.
- 1860 Thorpe-Beeston JG, Nicolaides KH, Felton CV, Butler J and McGregor AM, 1991. Maturation of the  
1861 secretion of thyroid hormone and thyroid-stimulating hormone in the fetus. *New England Journal*  
1862 *of Medicine*, 324, 532-536.
- 1863 Tovar E, Maisterrena JA and Chavez A, 1969. Iodine nutrition levels of school children in rural  
1864 Mexico. In: *Endemic Goitre*. PAHO Scientific Publication, No 193. Ed Stanbury JB. Pan American  
1865 Health Organization (PAHO), Washington D. C., USA, 411-415.
- 1866 Twyffels L, Massart C, Golstein PE, Raspe E, Van Sande J, Dumont JE, Beauwens R and Kruys V,  
1867 2011. Pendrin: the thyrocyte apical membrane iodide transporter? *Cellular Physiology and*  
1868 *Biochemistry*, 28, 491-496.
- 1869 Ubom GA, 1991. The goitre-soil-water-diet relationship: case study in Plateau State, Nigeria. *Science*  
1870 *of the Total Environment*, 107, 1-11.



- 1871 Valsta M, Lamberg-Allardt C, Bourdoux P, Laurinen M, Kärkkäinen M, Outila T, Aro A and Pietinen  
1872 P, 2003. Iodine status of middle-aged subjects in Finland. Helsinki: Finnish Society for Nutrition  
1873 Research.
- 1874 van Buuren S, Schönbeck Y and van Dommelen P, 2012. Collection, collation and analysis of data in  
1875 relation to reference heights and reference weights for female and male children and adolescents  
1876 (0-18 years) in the EU, as well as in relation to the age of onset of puberty and the age at which  
1877 different stages of puberty are reached in adolescents in the EU. Project developed on the  
1878 procurement project CT/EFSA/NDA/2010/01. 59 pp.
- 1879 van den Hove MF, Beckers C, Devlieger H, de Zegher F and De Nayer P, 1999. Hormone synthesis  
1880 and storage in the thyroid of human preterm and term newborns: effect of thyroxine treatment.  
1881 *Biochimie*, 81, 563-570.
- 1882 van Mil NH, Tiemeier H, Bongers-Schokking JJ, Ghassabian A, Hofman A, Hooijkaas H, Jaddoe VW,  
1883 de Muinck Keizer-Schrama SM, Steegers EA, Visser TJ, Visser W, Ross HA, Verhulst FC, de  
1884 Rijke YB and Steegers-Theunissen RP, 2012. Low urinary iodine excretion during early pregnancy  
1885 is associated with alterations in executive functioning in children. *Journal of Nutrition*, 142, 2167-  
1886 2174.
- 1887 Vanderpump MP, Lazarus JH, Smyth PP, Laurberg P, Holder RL, Boelaert K, Franklyn JA and British  
1888 Thyroid Association UKISG, 2011. Iodine status of UK schoolgirls: a cross-sectional survey.  
1889 *Lancet*, 377, 2007-2012.
- 1890 Vandevijvere S, Mourri AB, Amsalkhir S, Avni F, Van Oyen H and Moreno-Reyes R, 2012.  
1891 Fortification of bread with iodized salt corrected iodine deficiency in school-aged children, but not  
1892 in their mothers: a national cross-sectional survey in Belgium. *Thyroid*, 22, 1046-1053.
- 1893 Veinpalu M, Ambos A, Velbri S, Vaher Y and Podar T, 1996. Urinary iodine excretion in Estonian  
1894 children. *European Journal of Endocrinology*, 135, 248.
- 1895 VMNIS (Vitamin and Mineral Nutrition Information System), 2013. Database on Iodine Deficiency.  
1896 Iodine data by country. Available at:  
1897 <http://www.who.int/vmnis/database/iodine/countries/en/index.html>. Accessed December 2013.
- 1898 Vought RL and London WT, 1964. Iodine Intake and Excretion in Healthy Nonhospitalized Subjects.  
1899 *American Journal of Clinical Nutrition*, 15, 124-132.
- 1900 Vought RL and London WT, 1965. Effect of Dietary Iodine on Serum Inorganic and Salivary Iodine.  
1901 *Metabolism: Clinical and Experimental*, 14, 699-707.
- 1902 Vought RL and London WT, 1967. Iodine intake, excretion and thyroidal accumulation in healthy  
1903 subjects. *Journal of Clinical Endocrinology and Metabolism*, 27, 913-919.
- 1904 Vulsma T, Gons MH and de Vijlder JJ, 1989. Maternal-fetal transfer of thyroxine in congenital  
1905 hypothyroidism due to a total organification defect or thyroid agenesis. *New England Journal of*  
1906 *Medicine*, 321, 13-16.
- 1907 Wayne EJ, Koutras DA and Alexander WD, 1964. Clinical aspects of iodine metabolism. Blackwell,  
1908 Oxford, UK, pp. 303.
- 1909 WCRF/AICR (World Cancer Research Fund/American Institute for Cancer Research), 2007. Food,  
1910 Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. 537 pp.
- 1911 WHO (World Health Organization), 2004. Iodine status worldwide. WHO Global Database on Iodine  
1912 Deficiency.
- 1913 WHO Multicentre Growth Reference Study Group (World Health Organization), 2006. WHO Child  
1914 Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and  
1915 body mass index-for-age: Methods and development. 312 pp.

- 1916 WHO/FAO (World Health Organization/Food and Agriculture Organization of the United Nations),  
1917 2004. Vitamin and mineral requirements in human nutrition. Joint FAO/WHO Expert Consultation  
1918 on Human Vitamin and Mineral Requirements, Bangkok, Thailand. 341 pp.
- 1919 WHO/UNICEF (World Health Organization/ United Nations Children's Fund), 2007a. Reaching  
1920 optimal iodine nutrition in pregnant and lactating women and young children. Joint statement. 2 pp.
- 1921 WHO/UNICEF (World Health Organization/United Nations Children's Fund), 2007b. Iodine  
1922 deficiency in Europe. A continuing public health problem. 86 pp.
- 1923 WHO/UNICEF/ICCIDD (World Health Organization/United Nations Children's Fund/International  
1924 Council for the Control of Iodine Deficiency Disorders), 1996. Recommended iodine levels in salt  
1925 and guidelines for monitoring their adequacy and effectiveness. 13, 12.
- 1926 WHO/UNICEF/ICCIDD (World Health Organization/United Nations Children's Fund/International  
1927 Council for Control of Iodine Deficiency Disorders), 2001. Assessment of the iodine deficiency  
1928 disorders and monitoring their elimination. A guide for programme managers. WHO/NHD/01.1,  
1929 124 pp.
- 1930 WHO/UNICEF/ICCIDD (World Health Organization/United Nations Children's Fund/International  
1931 Council for Control of Iodine Deficiency Disorders), 2007. Assessment of the iodine deficiency  
1932 disorders and monitoring their elimination. A guide for programme managers. 108 pp.
- 1933 Widdowson EM and Spray CM, 1951. Chemical development in utero. Archives of Disease in  
1934 Childhood, 26, 205-214.
- 1935 Wiersinga WM, Podoba J, Srbecky M, van Vessel M, van Beeren HC and Platvoet-Ter Schiphorst  
1936 MC, 2001. A survey of iodine intake and thyroid volume in Dutch schoolchildren: reference values  
1937 in an iodine-sufficient area and the effect of puberty. European Journal of Endocrinology, 144,  
1938 595-603.
- 1939 Williams GR, 2008. Neurodevelopmental and neurophysiological actions of thyroid hormone. Journal  
1940 of Neuroendocrinology, 20, 784-794.
- 1941 Wu SY, Green WL, Huang WS, Hays MT and Chopra IJ, 2005. Alternate pathways of thyroid  
1942 hormone metabolism. Thyroid, 15, 943-958.
- 1943 Yassa L, Marqusee E, Fawcett R and Alexander EK, 2010. Thyroid hormone early adjustment in  
1944 pregnancy (the THERAPY) trial. Journal of Clinical Endocrinology and Metabolism, 95, 3234-  
1945 3241.
- 1946 Yoshimura M and Hershman JM, 1995. Thyrotropic action of human chorionic gonadotropin.  
1947 Thyroid, 5, 425-434.
- 1948 Young VR, 1986. Nutritional balance studies: indicators of human requirements or of adaptive  
1949 mechanisms? Journal of Nutrition, 116, 700-703.
- 1950 Zamrazil V, 2011. Iodine nutrition in Czech Republic. ICCIDD West-Central Europe regional  
1951 meeting. Satellite to 35th annual ETA meeting. September, 2011, Krakow, Poland.
- 1952 Zhao J, Wang P, Shang L, Sullivan KM, van der Haar F and Maberly G, 2000. Endemic goiter  
1953 associated with high iodine intake. American Journal of Public Health, 90, 1633-1635.
- 1954 Zhou SJ, Anderson AJ, Gibson RA and Makrides M, 2013. Effect of iodine supplementation in  
1955 pregnancy on child development and other clinical outcomes: a systematic review of randomized  
1956 controlled trials. American Journal of Clinical Nutrition.
- 1957 Zimmermann MB and Delange F, 2004. Iodine supplementation of pregnant women in Europe: a  
1958 review and recommendations. European Journal of Clinical Nutrition, 58, 979-984.
- 1959 Zimmermann MB, de Benoist B, Corigliano S, Jooste PL, Molinari L, Moosa K, Pretell EA, Al-Dallal  
1960 ZS, Wei Y, Zu-Pei C and Torresani T, 2006. Assessment of iodine status using dried blood spot  
1961 thyroglobulin: development of reference material and establishment of an international reference

1962 range in iodine-sufficient children. *Journal of Clinical Endocrinology and Metabolism*, 91, 4881-  
1963 4887.

1964 Zimmermann MB, 2007. The impact of iodised salt or iodine supplements on iodine status during  
1965 pregnancy, lactation and infancy. *Public Health Nutrition*, 10, 1584-1595.

1966 Zimmermann MB, 2009. Iodine deficiency in pregnancy and the effects of maternal iodine  
1967 supplementation on the offspring: a review. *American Journal of Clinical Nutrition*, 89, 668S-  
1968 672S.

1969 Zimmermann MB and Andersson M, 2011. Prevalence of iodine deficiency in Europe in 2010.  
1970 *Annales d'endocrinologie*, 72, 164-166.

1971 Zimmermann MB, 2012. The effects of iodine deficiency in pregnancy and infancy. *Paediatric and*  
1972 *Perinatal Epidemiology*, 26 Suppl 1, 108-117.

1973 Zois C, Stavrou I, Kalogera C, Svarna E, Dimoliatis I, Seferiadis K and Tsatsoulis A, 2003. High  
1974 prevalence of autoimmune thyroiditis in schoolchildren after elimination of iodine deficiency in  
1975 northwestern Greece. *Thyroid*, 13, 485-489.

1976 Zubiaur Cantalapiedra A, Zapico Alvarez-Cascos MD, Ruiz Perez L, Sanguino Lopez L, Sanchez  
1977 Serrano FJ, Alfayate Guerra R, Sanchez-Paya J, Guirao Carratala MD, Pico Alfonso A and Flores  
1978 Serrano J, 2007. [Iodine nutritional status in the school-aged population in Alicante (Spain)]. *An*  
1979 *Pediatr (Barc)*, 66, 260-266.

1980

1981

## APPENDICES

### Appendix A. Iodine concentration of human milk from healthy mothers in Europe

Reference	Number of women (n of samples)	Country	Total maternal intake		Stage of lactation	Iodine concentration (µg/L)			Information on iodine intake
			Measurement	Value		Mean ± SD	Median	Range (µg/L)	
Andersen et al. (2013)	67 (unsupplemented)	Denmark	Median (IQR) UI excretion (µg/day)	60 (44–83)	29 days		72	47–87 (IQR)	No information on the nature of supplementation and its duration
	60 (iodine-supplemented)			87 (55–144)	34 days		112	80–154 (IQR)	
Heidemann et al. (1986)	60	Sweden	Median (range) UI excretion (µg/g creatinine)	91.8 (34.5–316.1)	4–6 days		92.5	35–330	Healthy mothers under dietary iodine supplementation (no further information as to supplemented amounts etc.)
	41	Germany		32.6 (10.7–300)			25	12–195	
Costeira et al. (2009)	78	Portugal	Median (IQR) UI excretion (µg/L)	35 (15–98)	3 days		95	68–143 (IQR)	No women reported the use of iodine supplements or of iodised salt
	52			50 (28–84)	3 months		70	50–102 (IQR)	
Bader et al. (2005) <sup>(a)</sup>	12	Germany	Mean (µg/day)	116	1–10 days	184 ± 84	176		Iodised salt available and its use was promoted in the past
Kurtoglu et al. (2004)	70 (70)	Turkey	Not reported		5 days		73	9.50–355.6	Table salt is iodised but not industrial salt (it states that most families consume industrial salt)
Gokmen and Dagli (1995)	25	Turkey	Not reported		1–2 days	109 ± 50		45–208	No information on intake/supplementation/iodised salt
Nohr et al. (1994) <sup>(a)</sup>	(20)	Denmark	Not reported		5 days		54.0	12–117	No mention of iodisation but 36 % of mothers surveyed took supplements (not included in this table)
	(22)				5 days		36.0	7–89	
	(16)				5 days		54.5	19–178	
	(15)				5 days		28.7	9–39	

Reference	Number of women (n of samples)	Country	Total maternal intake		Stage of lactation	Iodine concentration (µg/L)			Information on iodine intake
			Measurement	Value		Mean ± SD	Median	Range (µg/L)	
Böhles et al. (1993)	(10) (21)	Germany	Not reported		5–7 days 1 week 3 months	55 ± 19	37 125	20–88	None taking additional iodine supplements. No information on iodised salt
Chierici et al. (1999)	10 (10)	Italy	Not reported		3 days 1 month 3 months	270 ± 140 150 ± 90 110 ± 40			No information on iodised salt. Dietary intake only reported for non-supplement and supplement users (the latter not included in this table)
Etling et al. (1986) (b)	(79)	Italy	Not reported		0–1 month	43.5 ± 2.5 <sup>(c)</sup>			No information on intake/supplementation/iodised salt
Etling and Gehin-Fouque (1984)	(68)	France	Not reported		Mature	81.6 ± 5.0 <sup>(c)</sup>			Young healthy women on an equilibrated diet (intake not given). No information on supplementation/iodised salt
Etling et al. (1983)	(77)	Italy	Not reported		1–28 days 1 day 5 days 16–52 days	54.0 ± 6.9 <sup>(c)</sup> 53.3 53.3 53.3–54.0			No information on intake/supplementation/iodised salt
Lahesmaa and Vilkkilä (1960)	42 (107) 18 (18)	Finland	Not reported		Not reported	53.3 ± 1.4 25.1 ± 1.6			The use of iodised salt was equally common in Turku and in Kuopio (~ 90 %). Kuopio (the second set of values) was an area where the incidence of endemic goitre was higher than the mean incidence for Finland. No information on supplementation

(a): Non-supplemented women only.

(b): Gestational age 37–42 weeks only.

(c): Mean ± standard error of the mean.

UI, urinary iodine; IQR, interquartile range.



## Appendix B. Urinary iodine concentrations in the European Union

The table below has been adapted from supplemental material by Andersson et al. (2012); VMNIS (2013). The median UI concentration ( $\mu\text{g/L}$ ) in school-aged children (6–12 years) in nationally representative surveys has been used to classify a population's iodine status (WHO/UNICEF/ICCIDD, 2007; Andersson et al., 2012). Hence, preference was given to studies carried out in school aged-children. In the review by Andersson et al. (2012), only surveys with a cross-sectional population-based sample frame were included, which used standard UI concentration assay techniques and reported at least on the following criteria: median and/or mean UI concentration ( $\mu\text{g/L}$ ), prevalence of inadequate iodine intake, proportion (%) of the population with UI concentration  $< 100 \mu\text{g/L}$ , UI concentration distribution (proportion of the population within the categories  $< 20$ ,  $20\text{--}49$ ,  $50\text{--}99$ ,  $100\text{--}199$ ,  $200\text{--}299$  and  $\geq 300 \mu\text{g/L}$ ). No data are available for Malta.

Country	Survey date	Survey level	Population group	Age range (years)	Sex	n	Median UIC ( $\mu\text{g/L}$ )	% with UIC $< 100 \mu\text{g/L}$	95 % CI	References
Austria	2000	Local (Carinthia)	Adults	NA	Men and women	430	191	21.4 <sup>(a)</sup>	17.6–25.3	Lind et al. (2002) <sup>(b)</sup>
Belgium	2010–2011	National	School-aged children	6–12	Boys and girls	1 507	113.1	39.4	36.9–41.9 <sup>(d)</sup>	Vandevijvere et al. (2012)
Bulgaria	2008	National	School-aged children	7–11	Boys and girls	355	182	11.2	7.9–14.5	Kovatcheva et al. (2011) <sup>(b)</sup>
Croatia	2009	National	School-aged children	6–10	Boys and girls	386	248	22.3	18.1–26.5	Kusic et al. (2012)
Cyprus	NA (published 2000)	Regional	School-aged children	9–10	Boys and girls	625	120	41.3 <sup>(a)</sup>	37.5–45.2	Erdogan et al. (2000) <sup>(b)</sup>
Czech Republic	2010	National	School-aged children	NA	Boys and girls	1 770	163	13.4	11.8–15.0	Zamrazil (2011) <sup>(b)</sup>
Denmark	2004–2005	Local	Adults	18–65	Men and women	3 554	101	48.1 <sup>(a)</sup>	46.5–49.8	Rasmussen et al. (2008) <sup>(b)</sup>
Estonia	1995	National	School-aged children	8–10	Boys and girls	1 840	65	67	64.9–69.1	Veinpalu et al. (1996) <sup>(b)</sup>
Finland	1997	Local	Adults	30–42	Men and women	342	164	28.3 <sup>(a)</sup>	23.5–33.0	Valsta et al. (2003) <sup>(b)</sup>
France	2006–2007	National	Adults	18–74	Men and women	1 867	136	33.2 <sup>(a)</sup>	31.1–35.3	Castetbon et al. (2009); Drees (2011) <sup>(b)</sup>

Country	Survey date	Survey level	Population group	Age range (years)	Sex	n	Median UIC (µg/L)	% with UIC < 100 µg/L	95 % CI	References
Germany	2003–2006	National	School-aged children	6–12	Boys and girls	6 635	122	38.8	37.6–40.0	Thamm et al. (2007) <sup>(b)</sup>
Greece	2001	Local	School-aged children and adolescents	12–18	Boys and girls	302	202	0	0–0	Zois et al. (2003) <sup>(b)</sup>
Hungary	1994–1997	National	School-aged children	7–11	Boys and girls	2 814	80	57.2 <sup>(a)</sup>	55.3–59.0	Farkas et al. (1997) <sup>(b)</sup>
Ireland	1999	Local	Adults	22–61	Men and women	132	82	56.2 <sup>(a)</sup>	47.7–64.7	Smyth (2002) (unpublished) <sup>(b)</sup>
Italy <sup>(e)</sup>	1999–2009	Regional, Local	School-aged children	NA	Boys and girls	4 911	96 <sup>(a)</sup>	50.2 <sup>(a)</sup>	48.8–51.6	Rapa et al. (1999a); Rapa et al. (1999b); Busnardo et al. (2003); Saggiorato et al. (2004); Marino et al. (2006); Saggiorato et al. (2006); Bonofiglio et al. (2009); Mazzarella et al. (2009) <sup>(b)</sup>
Latvia	2000	National	School-aged children	8–10	Boys and girls	599	59	76.8	73.4–80.2	Selga et al. (2000) <sup>(b)</sup>
Lithuania	1995	National	School-aged children	NA	Boys and girls	2 087	75	59.7 <sup>(a)</sup>	57.5–61.8	IDD Newsletter (2000) <sup>(b)</sup>
Luxembourg	2002	National	School-aged children	12–14	Boys and girls	498	148	32.7 <sup>(a)</sup>	28.6–36.8	Ministère de la Santé and Direction de la Santé (2002) <sup>(b)</sup>
Netherlands	1995–1996	Local	School-aged children and adolescents	6–18	Boys and girls	937	154	30.9 <sup>(a)</sup>	27.9–33.8	Wiersinga et al. (2001) <sup>(b)</sup>
Poland	2009–2011	Sub-national	School-aged children	6–12	Boys and girls	1 589	112	55	52.6–57.4	Szybinski (2011) <sup>(b)</sup>
Portugal	2010	National	School-aged children	NA	Boys and girls	3 680	105.5	47.1	45.5–48.7 <sup>(d)</sup>	Limbert et al. (2012)
Romania	2004–2005	National	School aged-children	6–7	Boys and girls	2 327	102	46.9	44.9–48.9	Alfred Ruescu Institute for Mother and Child Care (2005) <sup>(b)</sup>
Slovakia	2002	National	School aged-children	6–12	Boys and girls	1 744	183	15	13.3–16.7	Kostalova (2003) <sup>(b)</sup> (unpublished)

Country	Survey date	Survey level	Population group	Age range (years)	Sex	n	Median UIC (µg/L)	% with UIC < 100 µg/L	95 % CI	References
<b>Slovenia</b>	2003–2005	National	Adolescents	15–16	Boys and girls	2 464	140	23.5	21.8–25.2	Kotnik et al. (2006) <sup>(b)</sup>
<b>Spain</b> <sup>(e)</sup>	2000–2010	Local, district, state	School aged-children	NA	Boys and girls	7 314	141 <sup>(a)</sup>	34.8 <sup>(a)</sup>	33.7–35.9	Madueno Caro et al. (2001); Serra-Prat et al. (2003); Delgado et al. (2004); Santiago-Fernandez et al. (2004); Santiago et al. (2005); Zubiaur Cantalapiedra et al. (2007); Capdevila Bert et al. (2010) <sup>(b)</sup>
<b>Spain</b>	2009–2010	National	Adults	NA	Men and women	5 072 (total), 4 383 (with urine sample)	117.2			Soriguer et al. (2012)
<b>Sweden</b>	2006–2007	National	School-aged children	6–12	Boys and girls	857	125	30	26.9–33.1	Andersson et al. (2009) <sup>(b)</sup>
<b>United Kingdom</b>	2009	National	Adolescents	14–15	Boys and girls	737	80.1	68.8	64.9–72.7	Vanderpump et al. (2011) <sup>(b)</sup>

(a): Data missing from the original study report and calculated by Andersson et al. (2012).

(b): Cited in Andersson et al. (2012).

(c): VMNIS (2013).

(d): Calculated values (not in the original paper).

(e): Estimate based on pooled survey data (Andersson et al., 2012).

NA, not available; UIC, urinary iodine concentration; CI, confidence interval.

## GLOSSARY AND ABBREVIATIONS

Afssa	Agence française de sécurité sanitaire des aliments
AI	Adequate Intake
AR	Average Requirement
bw	Body weight
COMA	Committee on Medical Aspects of Food Policy
CV	Coefficient of variation
D-A-CH	Deutschland-Austria-Confoederatio Helvetica
DIT	Di-iodotyrosine
DRV	Dietary Reference Value
EAR	Estimated Average Requirement
EC	European Commission
EFSA	European Food Safety Authority
EU	European Union
FAO	Food and Agriculture Organization
ft4	Free thyroxine
ICCIDD	International Council for the Control of Iodine Deficiency Disorders
IDD	Iodine deficiency disorders
IOM	U.S. Institute of Medicine of the National Academy of Sciences
LRNI	Lowest Reference Nutrient Intake
LTI	Lowest Threshold Intake
MIT	Mono-iodotyrosine
NNR	Nordic Nutrition Recommendations
PRI	Population Reference Intake
RCT	randomised controlled trial
RDA	Recommended Dietary Allowance
RNI	Recommended Nutrient Intake
rT3	reverse T3, or 3,3',5'-triiodothyronine

SCF	Scientific Committee for Food
SCTD	Sub-clinical thyroid diseases
T3	Triiodothyronine or 3,5,3'-triiodothyronine
T4	Thyroxine or 3,5,3',5'-tetraiodothyronine
TBG	Thyroxine-binding globulin
Tg	Thyroglobulin
TPO	Thyroid peroxidase
TRH	Thyrotropin-releasing hormone
TSH	Thyroid-stimulating hormone, or thyrotropin
TTR	Transthyretin (pre-albumin)
UI	Urinary iodine
UL	Tolerable Upper Intake Level
UNICEF	United Nations Children's Fund
WHO	World Health Organization